Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

DOI: 10.1038/nature05016
Nature, 2006, 442, 916-9.

#	Paper	IF	Citations
1703	Alzheimer: 100 Years and Beyond. **2006**,		5
1702	Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2006**, 314, 130-3		4289
1701	Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. **2006**, 169, 1343-52		266
1700	[Nosology of dementias: the neuropathologist's point of view]. **2006**, 162, 921-8		8
1699	Aberrantly regulated proteins in frontotemporal dementia. **2006**, 348, 465-72		15
1698	TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2006**, 351, 602-11		1771
1697	Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases?. **2006**, 2, 658-65		38
1696	Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?. **2006**, 185, 381-4		23
1695	Research review: professional and clinical developments. **2006**, 4, 279-281		
1694	Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. **2006**, 129, 3115-23		162
1693	Frontotemporal dementia. **2006**, 19, 565-71		31
1692	Las noticias de Madrid (News from Madrid). **2006**, 1, 10		
1691	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature*, **2006**, 442, 920-4	50.4	1212
1690	A century of Alzheimer's disease. **2006**, 314, 777-81		1478
1689	Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. **2006**, 112, 539-49		264
1688	Frontotemporal dementia. **2006**, 6, 481-9		16
1687	Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. **2006**, 6, 44		61

1686	Frontotemporal dementia, chromosome 17, and progranulin. **2006**, 60, 275-7	9
1685	HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. **2006**, 60, 314-22	174
1684	Characteristics of frontotemporal dementia patients with a Progranulin mutation. **2006**, 60, 374-80	73
1683	Early frontotemporal dementia targets neurons unique to apes and humans. **2006**, 60, 660-7	244
1682	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. **2006**, 129, 3103-14	99
1681	Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. **2006**, 129, 3091-102	166
1680	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. **2006**, 129, 3081-90	259
1679	Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. **2006**, 129, 3051-65	132
1678	Mutations in progranulin explain atypical phenotypes with variants in MAPT. **2006**, 129, 3124-6	85
1677	Frontotemporal lobar degeneration through loss of progranulin function. **2006**, 129, 2808-10	17
1676	Untangling the tau gene association with neurodegenerative disorders. **2006**, 15 Spec No 2, R188-95	90
1675	Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. **2006**, 15 Spec No 2, R182-7	71
1674	Progranulin mutations in ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. **2006**, 3, 485-91	51
1673	Visualizing language deterioration in progressive aphasias. **2006**, 67, 1738-9	1
1672	A review of genome mutation and Alzheimer's disease. **2007**, 22, 15-33	41
1671	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. **2006**, 15, 2988-3001	463
1670	Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. **2007**, 78, 754-6	101
1669	Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. **2007**, 27, 10530-4	308

1668	Dissecting the complexity of frontotemporal dementia: genotypes, phenotypes, and phenocopies. **2007**, 69, 129-30	1
1667	Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. **2007**, 69, 140-7	70
1666	Clinicopathologic correlation in PGRN mutations. **2007**, 69, 1113-21	48
1665	A 34-year-old man with progressive behavioral and language disturbance. **2007**, 68, 68-74	4
1664	TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations. **2007**, 130, 1375-85	83
1663	TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. **2007**, 130, 1386-94	177
1662	A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. **2007**, 130, 1360-74	105
1661	Corticobasal syndrome associated with the A9D Progranulin mutation. **2007**, 66, 892-900	75
1660	Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. **2008**, 178, 316-21	58
1659	Clinical features of pathologic subtypes of behavioral--variant frontotemporal dementia. **2007**, 64, 1611-6	29
1658	Progranulin is a stress-response factor in fibroblasts subjected to hypoxia and acidosis. **2007**, 25, 280-5	45
1657	Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. **2007**, 64, 240-5	101
1656	Frontotemporal dementia and mania. **2007**, 164, 1811-6	28
1655	Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. **2007**, 4, 227-35	20
1654	Progranulin and tau gene mutations both as cause for dementia: 17q21 finally defined. **2007**, 64, 18-9	2
1653	Cognitive-behavioral profiles of neurodegenerative dementias: beyond Alzheimer's disease. **2007**, 20, 227-38	55
1652	Genetics of sporadic amyotrophic lateral sclerosis. **2007**, 16 Spec No. 2, R233-42	125
1651	Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. **2007**, 64, 1436-46	124

1650 Cognition and amyotrophic lateral sclerosis (ALS). **2007**, 22, 300-12 36

1649 Progressive nonfluent aphasia associated with a new mutation V363I in tau gene. **2007**, 22, 294-9 42

1648 Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. **2007**, 64, 43-7 134

1647 Current state and future directions of neurochemical biomarkers for Alzheimer's disease. **2007**, 45, 1421-34 58

1646 TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. **2007**, 64, 1388-94 148

1645 Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. **2007**, 104, 7319-26 110

1644 Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. **2007**, 64, 371-6 79

1643 Chapter 7 Ubiquitinopathies. **2007**, 165-185 2

1642 Involvement of granulin in estrogen-induced neurogenesis in the adult rat hippocampus. **2007**, 53, 297-307 55

1641 TDP-43 proteinopathies: a new class of proteinopathies. **2007**, 2, 549-557 2

1640 Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. **2007**, 64, 1148-53 47

1639 Primary progressive aphasia: a 25-year retrospective. **2007**, 21, S8-S11 54

1638 FRONTOTEMPORAL DEMENTIA. **2007**, 13, 87-108 4

1637 The diagnosis and course of frontotemporal dementia. **2007**, 21, 155-63 82

1636 Links between frontotemporal lobar degeneration, corticobasal degeneration, progressive supranuclear palsy, and amyotrophic lateral sclerosis. **2007**, 21, S31-8 41

1635 The genetics of frontotemporal lobar degeneration. **2007**, 20, 693-8 6

1634 Pick complex--historical introduction. **2007**, 21, S5-7 5

1633 Bibliography. Current World Literature. Pain: cancer. **2007**, 1, 63-9

1632	Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. **2007**, 21, 1-7	47
1631	Frontotemporal dementia and semantic dementia: anatomic variations on the same disease or distinctive entities?. **2007**, 21, S19-22	6
1630	Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. **2007**, 21, S79-87	52
1629	The neuropathology of FTD associated With ALS. **2007**, 21, S44-9	50
1628	Primary progressive aphasia: relationship between gender and severity of language impairment. **2007**, 20, 38-43	13
1627	Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. **2007**, 21, S14-8	173
1626	TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. **2007**, 66, 152-7	256
1625	Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. **2007**, 66, 142-51	150
1624	TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. **2007**, 66, 177-83	169
1623	A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. **2007**, 66, 884-91	106
1622	Dfhences frontotemporales. **2007**, 4, 1-14	1
1621	John Growdon. **2007**, 7, 28-30	
1620	Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. **2007**, 185, 110-8	144
1619	The complex aetiology of frontotemporal lobar degeneration. **2007**, 206, 1-10	25
1618	Tau isoform expression in frontotemporal dementia without tau deposition. **2007**, 14, 1182-5	6
1617	[Frontotemporal dementia]. **2007**, 36, 1477-84	2
1616	TDP-43 gene analysis in frontotemporal lobar degeneration. **2007**, 419, 1-4	40
1615	Appearance pattern of TDP-43 in Japanese frontotemporal lobar degeneration with ubiquitin-positive inclusions. **2007**, 419, 213-8	16

1614	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. **2007**, 424, 61-5	14
1613	Genetics and dementia: risk factors, diagnosis, and management. **2007**, 3, 418-27	25
1612	Demencia frontotemporal. Demencia con cuerpos de Lewy. Concepto. Manifestaciones cl?nicas. Manejo terap?utico. **2007**, 9, 4953-4961	
1611	TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. **2007**, 171, 227-40	376
1610	Clinical genetics of Parkinson's disease and related disorders. **2007**, 13 Suppl 3, S229-32	21
1609	Noncoding RNAs and RNA editing in brain development, functional diversification, and neurological disease. **2007**, 87, 799-823	242
1608	Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. **2007**, 130, 2770-88	746
1607	Frontotemporal lobar degeneration. **2007**, 25, 683-96, vi	23
1606	Parkinson-related dementias. **2007**, 25, 761-81, vii	24
1605	The genetics of frontotemporal dementia. **2007**, 25, 697-715, vi	13
1604	Variations in the coding and regulatory sequences of the angiogenin (ANG) gene are not associated to ALS (amyotrophic lateral sclerosis) in the Italian population. **2007**, 258, 123-7	34
1603	Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. **2007**, 4, 349-65	56
1602	Progranulin in frontotemporal lobar degeneration and neuroinflammation. **2007**, 4, 7	172
1601	Progranulin null mutations in both sporadic and familial frontotemporal dementia. **2007**, 28, 846-55	143
1600	Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. **2007**, 28, 416	91
1599	Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. **2007**, 39, 1434-6	152
1598	Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. **2007**, 6, 295-303	241
1597	Progranulin mutations in Dutch familial frontotemporal lobar degeneration. **2007**, 15, 369-74	48

1596	Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. **2007**, 8, 141-6	266
1595	Hereditary frontotemporal dementia caused by Tau gene mutations. **2007**, 17, 63-73	158
1594	Progressive supranuclear palsy: pathology and genetics. **2007**, 17, 74-82	193
1593	Frontotemporal lobar degeneration: current concepts in the light of recent advances. **2007**, 17, 104-14	61
1592	Abnormalities of the nucleus and nuclear inclusions in neurodegenerative disease: a work in progress. **2007**, 33, 2-42	66
1591	Progranulin: normal function and role in neurodegeneration. **2008**, 104, 287-97	96
1590	SHORT COMMUNICATIONS. **2007**, 14, 9-31	19
1589	Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. **2007**, 1184, 284-94	278
1588	TDP-43: a novel neurodegenerative proteinopathy. **2007**, 17, 548-55	93
1587	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. **2007**, 6, 652-62	242
1586	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. **2007**, 6, 857-68	174
1585	Genetic basis of frontotemporal dementia. **2007**, 6, 840-1	4
1584	Cognitive impairment in amyotrophic lateral sclerosis. **2007**, 6, 994-1003	402
1583	Semantic dementia: a unique clinicopathological syndrome. **2007**, 6, 1004-14	502
1582	RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies. **2007**, 64, 1701-14	31
1581	Late-onset frontotemporal dementia associated with a novel PGRN mutation. **2007**, 114, 1051-4	13
1580	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. **2007**, 113, 601-6	45
1579	The novel Tau mutation G335S: clinical, neuropathological and molecular characterization. **2007**, 113, 461-70	31

1578	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. **2007**, 113, 521-33	252
1577	Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. **2007**, 113, 543-8	43
1576	The neuropathology and clinical phenotype of FTD with progranulin mutations. **2007**, 114, 49-54	101
1575	TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. **2007**, 114, 63-70	162
1574	Frontotemporal lobar degeneration: recent progress in antemortem diagnosis. **2007**, 114, 23-9	18
1573	Frontotemporal lobar degeneration: clinical and pathological relationships. **2007**, 114, 31-8	244
1572	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. **2007**, 114, 5-22	837
1571	Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. **2007**, 114, 81-94	65
1570	Progranulin and frontotemporal lobar degeneration. **2007**, 114, 39-47	22
1569	Frontotemporal lobar degeneration--a coming of age. **2007**, 114, 1-4	2
1568	The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. **2007**, 8, 237-48	62
1567	The many ways to frontotemporal degeneration and beyond. **2007**, 28, 241-4	18
1566	The genetics of frontotemporal lobar degeneration. **2007**, 7, 434-42	36
1565	[Molecular neuropathology of Non-Alzheimer dementia]. **2008**, 29, 434-41	2
1564	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. **2008**, 9, 197-205	59
1563	Astrocytic tau pathology positively correlates with neurofibrillary tangle density in progressive supranuclear palsy. **2008**, 115, 623-8	13
1562	TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. **2008**, 116, 141-6	115
1561	TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. **2008**, 116, 135-40	17

1560	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. **2008**, 255, 488-94	36
1559	Progranulin gene mutation with an unusual clinical and neuropathologic presentation. **2008**, 23, 1168-73	35
1558	Novel progranulin mutation: screening for PGRN mutations in a Portuguese series of FTD/CBS cases. **2008**, 23, 1269-73	25
1557	Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan. **2008**, 23, 2344-8	23
1556	Progranulin locus deletion in frontotemporal dementia. **2008**, 29, 53-8	75
1555	Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. **2008**, 29, 512-21	61
1554	Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. **2008**, 29, 1373-86	116
1553	Education plays a different role in Frontotemporal Dementia and Alzheimer's disease. **2008**, 23, 796-800	12
1552	Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. **2008**, 47, 1524-32	90
1551	Gene expression study on peripheral blood identifies progranulin mutations. **2008**, 64, 92-6	83
1550	Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2008**, 64, 60-70	484
1549	Frontotemporal dementia and related disorders: deciphering the enigma. **2008**, 64, 4-14	146
1548	Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. **2008**, 17, 711-24	117
1547	Tau haplotype influences cerebral perfusion pattern in frontotemporal lobar degeneration and related disorders. **2008**, 117, 359-66	11
1546	Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases. **2008**, 7 Suppl 1, 12-27	13
1545	Animal models of Alzheimer's disease and frontotemporal dementia. **2008**, 9, 532-44	535
1544	Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. **2008**, 15, 377-85	58
1543	Frontotemporal dementia linked to chromosome 3 (FTD-3)--current concepts and the detection of a previously unknown branch of the Danish FTD-3 family. **2008**, 15, 667-70	32

1542	ALS and FTLD: two faces of TDP-43 proteinopathy. **2008**, 15, 772-80	104
1541	Clinical heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia because of Spatacsin mutations (SPG11). **2008**, 15, 1065-70	25
1540	Novel exon 1 progranulin gene variant in Alzheimer's disease. **2008**, 15, 1111-7	34
1539	Frontotemporal dementia and Parkinsonism linked to chromosome 17 in a young Australian patient with the G389R Tau mutation. **2008**, 34, 366-70	15
1538	Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland. **2008**, 8, 48	33
1537	Nuclear bodies in neurodegenerative disease. **2008**, 1783, 2195-206	39
1536	Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. **2008**, 7, 965-74	179
1535	Loss of progranulin function in frontotemporal lobar degeneration. **2008**, 24, 186-94	101
1534	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. **2008**, 31, 41-5	50
1533	Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies. **2008**, 5, 122-5	27
1532	Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings. **2008**, 63, 946-52	58
1531	Genetics of Parkinson's Disease. **2008**, 9-33	0
1530	A novel deletion in progranulin gene is associated with FTDP-17 and CBS. **2008**, 29, 427-35	94
1529	Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. **2008**, 29, 1276-8	9
1528	Genetic studies of GRN and IFT74 in amyotrophic lateral sclerosis. **2008**, 29, 1279-82	8
1527	Role of VEGF gene variability in longevity: a lesson from the Italian population. **2008**, 29, 1917-22	10
1526	Spatiotemporal expression pattern of progranulin in embryo implantation and placenta formation suggests a role in cell proliferation, remodeling, and angiogenesis. **2008**, 136, 247-57	27
1525	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. **2008**, 5, 207-24	197

1524	The aging brain. **2008**, 3, 41-66	425
1523	VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. **2008**, 1782, 744-8	163
1522	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. **2008**, 27, 336-49	279
1521	Tau, a biological marker of neurodegenerative diseases. **2008**, 89, 161-72	3
1520	Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2008**, 173, 182-94	225
1519	Frontotemporal dementia. **2008**, 7, 24-28	7
1518	Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. **2008**, 4, 414-20	13
1517	TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. **2008**, 19, 299-305	61
1516	The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. **2008**, 9, 323-38	101
1515	Demenze frontotemporali. **2008**, 8, 1-14	
1514	[Semantic dementia: reflexions of a French working group for diagnostic criteria and constitution of a patient cohort]. **2008**, 164, 343-53	22
1513	TDP-43 in neurodegenerative disorders. **2008**, 8, 969-78	31
1512	Progranulin genetic variability contributes to amyotrophic lateral sclerosis. **2008**, 71, 253-9	135
1511	Progressive anomia revisited: focal degeneration associated with progranulin gene mutation. **2007**, 13, 366-77	12
1510	Dementia and motor neuron disease. **2008**, 89, 431-41	
1509	Targeting angiogenin in therapy of amyotropic lateral sclerosis. **2008**, 12, 1229-42	32
1508	Frontotemporal lobar degeneration: clinical and pathologic overview. **2008**, 89, 343-64	7
1507	Clinical aspects of hereditary frontotemporal dementia. **2008**, 89, 365-76	

1506	Epidemiological aspects of frontotemporal dementia. **2008**, 89, 331-41	5
1505	Neuropathologic classification of dementias: introduction. **2008**, 89, 147-59	2
1504	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. **2008**, 181, 37-41	322
1503	CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. **2008**, 17, 313-22	112
1502	Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. **2008**, 17, 1349-62	96
1501	Distinct genetic forms of frontotemporal dementia. **2008**, 71, 1220-6	160
1500	Association between progranulin and beta-amyloid in dementia with Lewy bodies. **2008**, 23, 488-93	11
1499	The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. **2008**, 131, 72-89	76
1498	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. **2008**, 131, 706-20	198
1497	TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. **2008** , 16, 41-51	101
1496	Screening of hypoxia-inducible genes in sporadic ALS. **2008**, 9, 299-305	2
1495	Preliminary evidence that VEGF genetic variability confers susceptibility to frontotemporal lobar degeneration. **2008**, 11, 773-80	22
1494	Molecular genetics of Alzheimer's disease: an update. **2008**, 40, 562-83	175
1493	Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. **2008**, 71, 656-64	139
1492	Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. **2008**, 105, 15997-6002	178
1491	Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. **2008**, 283, 1744-1753	135
1490	Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. **2008**, 70, 1377-83	61
1489	Clinical aspects of TDP-43 proteinopathy, neurofilament inclusion body disease and dementias lacking distinctive proteinopathy. **2008**, 89, 377-82	2

1488	The genetics of frontotemporal dementia. **2008**, 89, 383-92	2
1487	Biological models in frontotemporal dementias. **2008**, 89, 449-55	
1486	Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. **2008**, 4, e1000193	339
1485	Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. **2008**, 71, 1191-7	54
1484	Progranulin variability has no major role in Parkinson disease genetic etiology. **2008**, 71, 1147-51	22
1483	Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci?. **2008**, 70, 686-94	36
1482	CSF biomarkers in frontotemporal lobar degeneration with known pathology. **2008**, 70, 1827-35	165
1481	Programmed cell death mechanisms in neurological disease. **2008**, 8, 173-86	42
1480	Patient care and management of frontotemporal lobar degeneration. **2008**, 23, 125-31	13
1479	Neuropathology of hereditary forms of frontotemporal dementia and parkinsonism. **2008**, 89, 393-414	9
1478	Is the glass half empty or half full? Genetically determined disease in frontotemporal dementia. **2008**, 71, 1216-7	2
1477	Clinical presentation of prodromal frontotemporal dementia. **2007**, 22, 456-67	16
1476	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. **2008**, 17, 3631-42	242
1475	New genes, new dilemmas: FTLD genetics and its implications for families. **2007**, 22, 507-15	19
1474	Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). **2008**, 65, 460-4	140
1473	Mapping the progression of progranulin-associated frontotemporal lobar degeneration. **2008**, 4, 455-60	36
1472	Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. **2008**, 131, 721-31	163
1471	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. **2008**, 131, 732-46	275

1470	Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. **2008**, 70, 1850-7	176
1469	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. **2008**, 12, 1367-76	7
1468	In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. **2008**, 5, 215-7	24
1467	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. **2008**, 105, 6439-44	317
1466	Brain magnetic resonance imaging structural changes in a pedigree of asymptomatic progranulin mutation carriers. **2008**, 11, 585-95	75
1465	Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene. **2008**, 65, 506-13	48
1464	NEUROIMAGING OF DISORDERS LEADING TO DEMENTIA. **2008**, 14, 144-163	1
1463	TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. **2008**, 67, 271-9	49
1462	Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions visualized with ubiquitin-binding protein p62 immunohistochemistry. **2008**, 67, 280-98	71
1461	Update on recent molecular and genetic advances in frontotemporal lobar degeneration. **2008**, 67, 635-48	26
1460	Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. **2008**, 67, 1122-36	38
1459	White matter tauopathy with globular glial inclusions: a distinct sporadic frontotemporal lobar degeneration. **2008**, 67, 963-75	95
1458	Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. **2008**, 21, 701-7	166
1457	New approaches to the treatment of frontotemporal lobar degeneration. **2008**, 21, 708-16	44
1456	Genetic assessment and management of dementia. **2008**, 8, 618-21	0
1455	Neurodegenerative disorders. 39-89	0
1454	Frontotemporal dementia: a topical review. **2008**, 21, 127-33	13
1453	GENETICS OF DEMENTIA. **2008**, 14, 29-48	

1452	The Neuronal Workspace Model: Conscious Processing and Learning. **2008**, 729-757	14
1451	Inflammation in neurodegenerative disorders: friend or foe?. **2008**, 1, 30-41	30
1450	An update on the toxicity of Abeta in Alzheimer's disease. **2008**, 4, 1033-42	28
1449	Molecular pathogenesis of frontotemporal lobar degeneration: basic science seminar in neurology. **2008**, 65, 700-4	2
1448	A review on primary progressive aphasia. **2007**, 3, 745-52	7
1447	Prion disease induced alterations in gene expression in spleen and brain prior to clinical symptoms. **2008**, 1, 29-50	14
1446	Neurogenetics of dementia. 27-44	
1445	Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease. **2009**, 18, 603-12	49
1444	Cognitive Impairment and Dementia. 245-288	3
1443	Neuropathology of dementia. 142-160	2
1442	The molecular basis of frontotemporal dementia. **2009**, 11, e23	57
1441	Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. **2009**, 284, 27416-24	118
1440	Absence of TARDBP gene mutations in an italian series of patients with frontotemporal lobar degeneration. **2009**, 28, 239-43	8
1439	Cortical atrophy and language network reorganization associated with a novel progranulin mutation. **2009**, 19, 1751-60	42
1438	No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration. **2009**, 28, 471-5	6
1437	Clinical features and diagnosis of frontotemporal dementia. **2009**, 24, 140-148	10
1436	A schizophrenia gene locus on chromosome 17q21 in a new set of families of Mexican and central american ancestry: evidence from the NIMH Genetics of schizophrenia in latino populations study. **2009**, 166, 442-9	29
1435	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. **2009**, 132, 583-91	315

1434	Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia. **2009**, 106, 12168-73	66
1433	[Frontotemporal lobar degeneration]. **2009**, 77, 295-304	5
1432	Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. **2009**, 17, 607-13	69
1431	Frontotemporal dementia neuroimaging: a guide for clinicians. **2009**, 24, 160-167	12
1430	A common biological mechanism in cancer and Alzheimer's disease?. **2009**, 6, 196-204	126
1429	Autosomal dominant subcortical gliosis presenting as frontotemporal dementia. **2009**, 72, 260-7	12
1428	Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. **2009**, 72, 813-20	108
1427	"Frontotemporoparietal" dementia: clinical phenotype associated with the c.709-1G>A PGRN mutation. **2009**, 73, 1367-74	41
1426	ADAMTS-7, a direct target of PTHrP, adversely regulates endochondral bone growth by associating with and inactivating GEP growth factor. **2009**, 29, 4201-19	88
1425	Progranulin and beta-amyloid distribution: a case report of the brain from preclinical PS-1 mutation carrier. **2009**, 24, 456-60	17
1424	Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. **2009**, 58, 627-36	118
1423	Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. **2009**, 18, 3725-38	31
1422	Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia. **2009**, 29, 8506-11	100
1421	Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. **2009**, 33, 379-85	97
1420	Progranulin is expressed within motor neurons and promotes neuronal cell survival. **2009**, 10, 130	128
1419	Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression following axotomy: implications for TDP-43 in the physiological response to neuronal injury. **2009**, 1249, 202-11	173
1418	Cytosolic TDP-43 expression following axotomy is associated with caspase 3 activation in NFL-/- mice: support for a role for TDP-43 in the physiological response to neuronal injury. **2009**, 1296, 176-86	73
1417	An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population. **2009**, 150B, 747-50	34

1416	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. **2009**, 65, 603-9	185
1415	Intention tremor in essential tremor: Prevalence and association with disease duration. **2009**, 24, 626-7	86
1414	Increase in the tactile catchment area of a sensory trick for alleviating blepharospasm following pallidal DBS. **2009**, 24, 624-6	3
1413	Pseudohypoparathyroidism manifesting with paroxysmal dyskinesias and seizures. **2009**, 24, 623-4	16
1412	Hiccups associated with levodopa in Parkinson's disease. **2009**, 24, 621-22	25
1411	Recurrent hemichorea following a single infarction in the contralateral subthalamic nucleus. **2009**, 24, 617-8	14
1410	Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. **2009** , 24, 618-9	16
1409	Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient. **2009**, 24, 627-8	25
1408	Tramadol hydrochloride use and acute deterioration in Parkinson's disease tremor. **2009**, 24, 622-3	5
1407	Reported mutations in GIGYF2 are not a common cause of Parkinson's disease. **2009**, 24, 619-20	24
1406	Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. **2009**, 24, 2042-58	49
1405	The granulin gene family: from cancer to dementia. **2009**, 31, 1245-54	258
1404	Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. **2009**, 10, 27-34	13
1403	Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. **2009**, 117, 137-49	358
1402	Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. **2009**, 117, 125-36	248
1401	Clinicopathological characterization of Pick's disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions. **2009**, 117, 429-44	59
1400	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. **2009**, 118, 359-69	25
1399	Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. **2009**, 118, 349-58	103

1398	TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. **2009**, 118, 633-45	110
1397	Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. **2009**, 118, 647-58	65
1396	Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases. **2009**, 256, 1205-14	141
1395	Frequency of progranulin mutations in a German cohort of 79 frontotemporal dementia patients. **2009**, 256, 2043-51	9
1394	A model-based approach to understanding apraxia in Corticobasal Syndrome. **2009**, 19, 47-63	20
1393	microRNAs in CNS disorders. **2009**, 11, 162-72	61
1392	TDP-43 and frontotemporal dementia. **2009**, 9, 353-8	12
1391	Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. **2009**, 219, 173-81	63
1390	Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo. **2009**, 100, 434-40	25
1389	Understanding microRNAs in neurodegeneration. **2009**, 10, 837-41	226
1388	Genomic survey of prepulse inhibition in mouse chromosome substitution strains. **2009**, 8, 806-16	11
1387	Frontotemporal lobar degeneration with ubiquitinated tau-negative inclusions and additional alpha-synuclein pathology but also unusual cerebellar ubiquitinated p62-positive, TDP-43-negative inclusions. **2009**, 29, 466-71	16
1386	Genetic testing in familial AD and FTD: mutation and phenotype spectrum in a Danish cohort. **2009**, 76, 205-9	19
1385	Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. **2009**, 110, 1082-94	132
1384	Low prevalence of progranulin mutations in Finnish patients with frontotemporal lobar degeneration. **2009**, 16, 27-30	26
1383	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. **2009**, 16, 297-309	143
1382	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. **2009**, 132, 2932-46	223
1381	Development of macrophages of cyprinid fish. **2009**, 33, 411-29	36

1380	I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. **2009**, 390, 710-5	22
1379	Recent insights into the molecular genetics of dementia. **2009**, 32, 451-61	47
1378	No association of TDP-43 with sporadic frontotemporal dementia. **2009**, 30, 157-9	29
1377	Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. **2009**, 30, 752-8	55
1376	Prominent phenotypic variability associated with mutations in Progranulin. **2009**, 30, 739-51	150
1375	Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. **2009**, 30, 1825-33	36
1374	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. **2009**, 30, 656-65	29
1373	Pallidonigral TDP-43 pathology in Perry syndrome. **2009**, 15, 281-6	72
1372	Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. **2009**, 16, 1131-5	112
1371	The effect of DNMTs and MBPs on hypomethylation in systemic lupus erythematosus. **2009**, 53, 236-8	6
1370	Progranulin, a secreted tumorigenesis and dementia-related factor, regulates mouse hair growth. **2009**, 53, 234-6	4
1369	Progranulin (PGRN) expression in ALS: an immunohistochemical study. **2009**, 276, 9-13	35
1368	Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease. **2009**, 287, 291-3	72
1367	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. **2009**, 2, 30	101
1366	Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. **2009**, 194, 298-305	133
1365	Frontotemporal dementias: update on recent developments in molecular genetics and neuropathology. **2009**, 60, 117-22	5
1364	Progressive language impairments: Definitions, diagnoses, and prognoses. **2009**, 23, 302-326	11
1363	Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. **2009**, 174, 1037-47	58

1362	Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology. **2009**, 66, 121-4	43
1361	Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation. **2009**, 118, 561-73	60
1360	Frontotemporal dementia. 45-55	
1359	Animal models of dementia. 131-141	
1358	Early clinical features of the parkinsonian-related dementias. 197-212	2
1357	Dementia treatment. 213-253	2
1356	The role of CHMP2B in frontotemporal dementia. **2009**, 37, 208-12	52
1355	Roles of progranulin in sexual differentiation of the developing brain and adult neurogenesis. **2009**, 55, 351-5	35
1354	TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. **2009**, 68, 262-73	75
1353	Microglial upregulation of progranulin as a marker of motor neuron degeneration. **2010**, 69, 1191-200	55
1352	Frontotemporal dementia and pharmacologic interventions. **2010**, 22, 19-29	19
1351	Prevalence of primitive reflexes and Parkinsonian signs in dementia. **2010**, 37, 601-7	19
1350	Frontotemporal degeneration. **2010**, 16, 191-211	7
1349	Update on frontotemporal dementia. **2010**, 16, 16-22	40
1348	Biomarkers in frontotemporal lobar degeneration. **2010**, 23, 643-8	13
1347	Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. **2010**, 67, 171-7	51
1346	Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. **2010**, 67, 1238-50	74
1345	Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. **2010**, 87, 890-7	110

1344	Contemporary approaches to Alzheimer's disease and frontotemporal dementia. **2011**, 670, 1-9	7
1343	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. **2010**, 119, 111-22	56
1342	Sporadic corticobasal syndrome due to FTLD-TDP. **2010**, 119, 365-74	46
1341	Progranulin expression is upregulated after spinal contusion in mice. **2010**, 119, 123-33	52
1340	The enigmatic roles of microglial versus neuronal progranulin in neurological disease. **2010**, 119, 107-9	3
1339	TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. **2010**, 120, 43-54	59
1338	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. **2010**, 120, 33-41	198
1337	Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. **2010**, 117, 227-39	47
1336	Neurodegenerative dementia and parkinsonism. **2010**, 14, 37-44	4
1335	Progranulin promotes neurite outgrowth and neuronal differentiation by regulating GSK-3**2010**, 1, 552-62	93
1334	Frontotemporal dementia and primary progressive aphasia: an update. **2010**, 10, 504-11	14
1333	TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. **2010**, 9, 995-1007	661
1332	Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview. **2010**, 43, 438-52	57
1331	Progranulin-associated primary progressive aphasia: a distinct phenotype?. **2010**, 48, 288-97	78
1330	A changing landscape for advance directives in dementia research. **2010**, 70, 623-30	34
1329	Progranulin deficiency leads to enhanced cell vulnerability and TDP-43 translocation in primary neuronal cultures. **2010**, 1366, 1-8	51
1328	Progranulin expression in the developing and adult murine brain. **2010**, 518, 3931-47	94
1327	Dementia services in Canada. **2010**, 25, 876-80	5

1326	A thorough assessment of benign genetic variability in GRN and MAPT. **2010**, 31, E1126-40	21
1325	Granulin-epithelin precursor binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. **2010**, 62, 2023-36	85
1324	Progranulin (granulin/epithelin precursor) and its constituent granulin repeats repress transcription from cellular promoters. **2010**, 223, 224-33	12
1323	Clinical implications of gene discovery in Parkinson's disease and parkinsonism. **2010**, 25 Suppl 1, S15-20	14
1322	Development and application of mass spectrometric methods for the analysis of progranulin N-glycosylation. **2010**, 73, 1479-90	26
1321	Progranulin modulates zebrafish motoneuron development in vivo and rescues truncation defects associated with knockdown of Survival motor neuron 1. **2010**, 5, 41	49
1320	Mutations in CHMP2B are not a cause of frontotemporal lobar degeneration in Finnish patients. **2010**, 17, 1393-5	11
1319	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. **2010**, 112, 1305-15	68
1318	Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. **2010**, 115, 735-47	51
1317	Review: Recent progress in frontotemporal lobar degeneration. **2010**, 36, 4-16	6
1316	Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. **2010**, 36, 97-112	55
1315	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. **2010**, 42, 234-9	361
1314	Deciphering genetic susceptibility to frontotemporal lobar dementia. **2010**, 42, 189-90	7
1313	Open chromatin and diabetes risk. **2010**, 42, 190-2	9
1312	Initiation and propagation of neurodegeneration. **2010**, 16, 1201-4	38
1311	The future of genetic research on neurodegeneration. **2010**, 16, 1215-7	17
1310	Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. **2010**, 30, 170-81	87
1309	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. **2010**, 30, 103-12	135

1308	Frontotemporal Dementia. **2010**, 428-432	
1307	Old-age psychiatry. **2010**, 635-692	1
1306	HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. **2010**, 17, 568-77	65
1305	GRN variability contributes to sporadic frontotemporal lobar degeneration. **2010**, 19, 171-7	27
1304	MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. **2010**, 5, e10551	68
1303	Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. **2010**, 5, e13368	100
1302	FUS/TLS genetic variability in sporadic frontotemporal lobar degeneration. **2010**, 19, 1317-22	2
1301	The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. **2010**, 67, 161-70	143
1300	Error in Figure in: Cellular Mechanisms of Central Nervous System Repair by Natural Autoreactive Monoclonal Antibodies. **2010**, 67, 147	
1299	Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. **2010**, 24, 1879-92	91
1298	Progress on progranulin. **2010**, 67, 145-7	3
1297	Genetic causes of frontotemporal degeneration. **2010**, 23, 260-8	20
1296	Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. **2010**, 24, 4639-47	140
1295	Mouse models of neurodegenerative diseases: criteria and general methodology. **2010**, 602, 323-45	18
1294	TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. **2010**, 13, 509-17	65
1293	Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia. **2010**, 16, 273-9	30
1292	Growth factors as active participants in carcinogenesis: a perspective. **2010**, 47, 77-97	34
1291	Survival in progressive supranuclear palsy and frontotemporal dementia. **2010**, 81, 441-5	66

1290	Genetics of frontotemporal lobar degeneration. **2010**, 13, S55-62	3
1289	Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. **2010**, 133, 300-6	205
1288	Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. **2010**, 21, 251-72	44
1287	Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. **2010**, 133, 1143-54	164
1286	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. **2010**, 11, 497-503	13
1285	Frontotemporal dementias: Recent advances and current controversies. **2010**, 13, S74-80	12
1284	Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?. **2010** , 75, 2212-20	65
1283	MicroRNAs in neurodegenerative disorders. **2010**, 9, 1717-21	19
1282	Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. **2010**, 7, 170-4	71
1281	New insights into biological markers of frontotemporal lobar degeneration spectrum. **2010**, 17, 1002-9	12
1280	Frontotemporal Dementia. **2010**, 34, 397-416	
1279	Corticobasal Ganglionic Degeneration. **2010**, 375-396	1
1278	Frontotemporal lobar degeneration with motor neuron disease showing severe and circumscribed atrophy of anterior temporal lobes. **2010**, 297, 92-6	7
1277	Hypoxia induces up-regulation of progranulin in neuroblastoma cell lines. **2010**, 57, 893-8	26
1276	Animal models reveal role for tau phosphorylation in human disease. **2010**, 1802, 860-71	63
1275	Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. **2010**, 391, 242-7	19
1274	Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. **2010**, 31, 1903-11	26
1273	Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. **2010**, 68, 654-67	368

1272	Molecular pathways of frontotemporal lobar degeneration. **2010**, 33, 71-88	34
1271	Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. **2010**, 177, 311-24	214
1270	miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. **2010**, 177, 334-45	146
1269	TAR DNA-binding protein 43 in neurodegenerative disease. **2010**, 6, 211-20	322
1268	Role of progranulin as a biomarker for Alzheimer's disease. **2010**, 4, 37-50	19
1267	TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. **2010**, 19, R46-64	695
1266	Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. **2010**, 24, 375-98	263
1265	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. **2011**, 82, 476-86	408
1264	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. **2011**, 134, 2456-77	2970
1263	Neuropathologie des d□□escences lobaires frontotemporales. **2011**, 2, 47-51	1
1262	Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. **2011**, 140, 344-55	114
1261	Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene. **2011**, 70, e43-4	29
1260	Tau Pathology. **2011**, 83-132	1
1259	rs5848 polymorphism and serum progranulin level. **2011**, 300, 28-32	64
1258	Clinicopathological study of diffuse neurofibrillary tangles with calcification. With special reference to TDP-43 proteinopathy and alpha-synucleinopathy. **2011**, 301, 77-85	10
1257	Increased progranulin in the skin of amyotrophic lateral sclerosis: an immunohistochemical study. **2011**, 309, 110-4	11
1256	Parkinson's disease: genetics and pathogenesis. **2011**, 6, 193-222	519
1255	Animal Models of Dementia. **2011**,	7

1254	Alzheimer's Disease and Frontotemporal Dementia. **2011**,	3
1253	Troubles de l□ttention chez un homme de 71 ans. **2011**, 2, 215-228	
1252	Progranulin is a chemoattractant for microglia and stimulates their endocytic activity. **2011**, 178, 284-95	86
1251	Use of peripheral blood transcriptome biomarkers for epilepsy prediction. **2011**, 497, 213-7	13
1250	TDP-43 and FUS: a nuclear affair. **2011**, 34, 339-48	154
1249	Biomarker-based dissection of neurodegenerative diseases. **2011**, 95, 520-34	66
1248	Biomarkers in frontotemporal lobar degenerations--progress and challenges. **2011**, 95, 636-48	30
1247	On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. **2011**, 95, 649-62	43
1246	No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. **2011**, 32, 754-5	38
1245	No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort. **2011**, 32, 1157-8	14
1244	Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. **2011**, 32, 555.e1-8	26
1243	Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. **2011**, 32, 758.e1-7	28
1242	Extracellular progranulin protects cortical neurons from toxic insults by activating survival signaling. **2011**, 32, 2326.e5-16	78
1241	Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. **2011**, 71, 1030-42	105
1240	Wnt signaling as a potential therapeutic target for frontotemporal dementia. **2011**, 71, 955-7	11
1239	Progranulin enhances neural progenitor cell proliferation through glycogen synthase kinase 3□ phosphorylation. **2011**, 185, 106-15	49
1238	Patterning spinal motor activity in the absence of synaptic excitation. **2011**, 71, 957-9	
1237	An analysis of global research funding for the frontotemporal dementias: 1998-2008. **2011**, 7, 142-50	4

1236	Deterioro cognitivo vascular. Demencia por cuerpos de Lewy. Demencia frontotemporal. Otras demencias. **2011**, 10, 5145-5155	
1235	Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN). **2010**, 22, 1123-33	16
1234	A novel progranulin mutation causing frontotemporal lobar degeneration with heterogeneous phenotypic expression. **2011**, 23, 7-12	16
1233	Proteomic analysis of hippocampal dentate granule cells in frontotemporal lobar degeneration: application of laser capture technology. **2011**, 2, 24	13
1232	A non-specific effect associated with conditional transgene expression based on Cre-loxP strategy in mice. **2011**, 6, e18778	18
1231	C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking. **2011**, 6, e21023	68
1230	Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. **2011**, 6, e23075	66
1229	Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteins. **2011**, 6, e26454	43
1228	The Neuropathology of the Dementing Disorders. **2011**, 235-261	
1227	From genotype to phenotype: two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder. **2011**, 27, 791-7	59
1226	Age-dependent changes in progranulin expression in the mouse brain. **2011**, 57, 113-9	36
1225	Genetics of dementia. **2011**, 17, 326-42	5
1224	Involvement of progranulin in the enhancement of hippocampal neurogenesis by voluntary exercise. **2011**, 22, 881-6	20
1223	Recent breakthroughs in the understanding of frontotemporal lobar degeneration and its related disorders. **2011**, 8, 222-3	
1222	Frontotemporal dementia caused by CHMP2B mutations. **2011**, 8, 246-51	73
1221	Genetic contributors to frontotemporal lobar degeneration: beyond monogenic disease. **2011**, 11, 988-1001	1
1220	FTD and ALS: a tale of two diseases. **2011**, 8, 273-94	149
1219	Helping the FTD patient-caregiver dyad. **2011**, 38, 671-2	

1218	Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer disease: focus on TNF- and IL-1 **2011**, 6, 757-769	9
1217	Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred. **2011**, 24, 253-9	57
1216	Frontotemporal Dementia. **2011**, 145-178	1
1215	Cerebrospinal fluid biomarkers in Progranulin mutations carriers. **2011**, 27, 781-90	42
1214	Variability of the clinical phenotype in an Italian family with dementia associated with an intronic deletion in the GRN gene. **2011**, 26, 583-90	10
1213	Frontotemporal dementia and parkinsonism linked to chromosome 17--the first Polish family. **2011**, 18, 535-7	8
1212	Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. **2011**, 14, 459-68	827
1211	Progranulin: a promising therapeutic target for rheumatoid arthritis. **2011**, 585, 3675-80	83
1210	The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. **2011**, 332, 478-84	517
1209	Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. **2011**, 77, 1636-43	57
1208	Domain-specific monoclonal antibodies produced against human PGRN. **2011**, 30, 271-8	10
1207	Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. **2011**, 72, 245-56	3267
1206	Pathological correlates of frontotemporal lobar degeneration in the elderly. **2011**, 121, 365-71	64
1205	Neuropathological background of phenotypical variability in frontotemporal dementia. **2011**, 122, 137-53	311
1204	Clinicopathologic study on an ALS family with a heterozygous E478G optineurin mutation. **2011**, 122, 223-9	51
1203	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. **2011**, 122, 673-90	245
1202	Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. **2011**, 122, 657-71	120
1201	C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. **2011**, 122, 653-5	8

1200	Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. **2011**, 32, 9-16	60
1199	Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). **2011**, 32, 653-9	3
1198	Fronto-temporal lobar degeneration: neuropathology in 60 cases. **2011**, 118, 753-64	9
1197	Modes of A□toxicity in Alzheimer's disease. **2011**, 68, 3359-75	68
1196	TDP-43 variants of frontotemporal lobar degeneration. **2011**, 45, 390-401	20
1195	Cellular effects of progranulin in health and disease. **2011**, 45, 549-60	77
1194	Human genetics as a tool to identify progranulin regulators. **2011**, 45, 532-7	4
1193	Genetic counseling for frontotemporal dementias. **2011**, 45, 706-9	8
1192	Clinical aspects of familial forms of frontotemporal dementia associated with parkinsonism. **2011**, 45, 359-65	14
1191	Structure, function, and mechanism of progranulin; the brain and beyond. **2011**, 45, 538-48	97
1190	Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). **2011**, 45, 384-9	223
1189	Pathogenesis of the tauopathies. **2011**, 45, 425-31	93
1188	Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. **2011**, 45, 366-71	5
1187	Potential mechanisms of progranulin-deficient FTLD. **2011**, 45, 574-82	21
1186	Progranulin and TDP-43: mechanistic links and future directions. **2011**, 45, 561-73	44
1185	Parkinsonism and frontotemporal dementia: the clinical overlap. **2011**, 45, 343-9	39
1184	Frontotemporal dementia: from Mendelian genetics towards genome wide association studies. **2011**, 45, 500-15	21
1183	Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression. **2011**, 11, 63	7

1182	FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases. **2011**, 11, 50	22
1181	Low plasma progranulin levels in children with autism. **2011**, 8, 111	29
1180	Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. **2011**, 8, 65	60
1179	Aberrant septin 11 is associated with sporadic frontotemporal lobar degeneration. **2011**, 6, 82	13
1178	Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. **2011**, 12, 527	39
1177	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. **2011**, 134, 808-15	90
1176	Behavioral genetics of neurodegenerative disorders. **2012**, 12, 615-31	3
1175	Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. **2011**, 4, ra65	41
1174	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. **2011**, 68, 488-97	93
1173	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. **2011**, 134, 2548-64	65
1172	Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. **2011**, 68, 329-37	63
1171	Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity. **2011**, 5, 250-7	20
1170	Recent insights into the involvement of progranulin in frontotemporal dementia. **2011**, 9, 632-42	12
1169	Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease. **2011**, 18, 2655-60	9
1168	Chromosome 17 in FTLD: from MAPT tau to progranulin and back. **2011**, 8, 229-36	5
1167	Novel progranulin mutation detected in 2 patients with FTLD. **2011**, 25, 173-8	8
1166	Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. **2011**, 39, 8677-88	88
1165	Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. **2011**, 25, 364-8	68

1164	Involvement of progranulin in hypothalamic glucose sensing and feeding regulation. **2011**, 152, 4672-82	19
1163	RNA-binding proteins with prion-like domains in ALS and FTLD-U. **2011**, 5, 179-87	114
1162	Progranulin deficiency decreases gross neural connectivity but enhances transmission at individual synapses. **2011**, 31, 11126-32	66
1161	Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. **2011**, 21, 1572-82	149
1160	Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. **2011**, 286, 16101-8	121
1159	Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders. **2011**, 197-240	2
1158	Clinical overview and phenomenology of movement disorders. **2011**, 1-35	4
1157	rs5848 variant of progranulin gene is a risk of Alzheimer's disease in the Taiwanese population. **2011**, 8, 216-20	35
1156	Genetic background predicts poor prognosis in frontotemporal lobar degeneration. **2011**, 8, 289-95	17
1155	Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. **2011**, 17, 1194-201	43
1154	New front against TNF. **2011**, 4, 328-328	
1153	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. **2011**, 82, 196-203	146
1152	Abhorring the vacuum: use of Alzheimer disease medications in frontotemporal dementia. **2011**, 11, 709-17	43
1151	Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. **2011**, 31, 1885-94	109
1150	An algorithm for genetic testing of frontotemporal lobar degeneration. **2011**, 76, 475-83	57
1149	TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. **2011**, 76, 467-74	174
1148	Brain perfusion patterns in familial frontotemporal lobar degeneration. **2011**, 77, 384-92	14
1147	The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. **2011**, 134, 2478-92	178

1146	A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. **2011**, 108, 4441-6	95
1145	Similar clinical and neuroimaging features in monozygotic twin pair with mutation in progranulin. **2012**, 78, 1245-9	13
1144	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. **2012**, 135, 794-806	306
1143	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. **2012**, 135, 693-708	420
1142	Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. **2012**, 6, 48	65
1141	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. **2012**, 135, 765-83	277
1140	The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. **2012**, 44, 817-28	141
1139	Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: a multicenter Italian study. **2012**, 9, 121-7	77
1138	Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. **2012**, 287, 32298-306	149
1137	Frontotemporal dementia: implications for understanding Alzheimer disease. **2012**, 2, a006254	101
1136	Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. **2012**, 287, 19355-65	91
1135	Frontotemporal dementia, manifested as schizophrenia, with decreased heterochromatin on chromosome 1. **2012**, 2012, 937518	6
1134	Neuropsychological features of asymptomatic c.709-1G>A progranulin mutation carriers. **2012**, 18, 1086-90	15
1133	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische Ansätze in der Diagnose der Frontotemporalen Lobärdegeneration. **2012**, 36,	1
1132	Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. **2012**, 135, 819-32	80
1131	Modified yeast-two-hybrid system to identify proteins interacting with the growth factor progranulin. **2012**,	10
1130	The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype. **2012**, 28, 759-63	11
1129	The brain-derived neurotrophic factor Val66Met polymorphism is associated with reduced hippocampus perfusion in frontotemporal lobar degeneration. **2012**, 31, 243-51	15

1128	Clinical, neuropathological, and genetic characteristics of the novel IVS9+1delG GRN mutation in a patient with frontotemporal dementia. **2012**, 30, 83-90	7
1127	[FTDP-17 presenting amnestic MCI as an initial symptom: case report]. **2012**, 52, 73-8	1
1126	Estimating the age of the most common Italian GRN mutation: walking back to Canossa times. **2013**, 33, 69-76	14
1125	Ask the Experts: Progress in diagnosing frontotemporal lobar dementia. **2012**, 2, 251-254	
1124	A Possible Key Role for Redox-Active Metal Ions and Soluble Oligomers in Neurodegenerative Disease. **2012**, 23-44	
1123	Characterization of a family with c9FTD/ALS associated with the GGGGCC repeat expansion in C9ORF72. **2012**, 69, 1164-9	16
1122	TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. **2012**, 287, 15635-47	190
1121	TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. **2012**, 32, 11213-27	143
1120	Using Exome Sequencing to Reveal Mutations in TREM2 Presenting as a Frontotemporal Dementia□ke Syndrome Without Bone Involvement. **2012**, 1	5
1119	Mouse models of frontotemporal dementia. **2012**, 72, 837-49	61
1118	The genetics and neuropathology of frontotemporal lobar degeneration. **2012**, 124, 353-72	206
1117	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. **2012**, 124, 373-82	69
1116	Frontotemporal lobar degeneration: current knowledge and future challenges. **2012**, 259, 2278-86	31
1115	Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. **2012**, 2, 789-98	103
1114	Progranulin compensates for blocked IGF-1 signaling to promote myotube hypertrophy in C2C12 myoblasts via the PI3K/Akt/mTOR pathway. **2012**, 586, 3485-92	44
1113	Medical and environmental risk factors associated with frontotemporal dementia: a case-control study in a veteran population. **2012**, 8, 204-10	58
1112	APOE: a risk factor for multiple disorders. **2012**, 20, 545-8	6
1111	Progranulin axis and recent developments in frontotemporal lobar degeneration. **2012**, 4, 4	14

1110	Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. **2012**, 4, 27	27
1109	Cognitive and behavioral features of c9FTD/ALS. **2012**, 4, 29	16
1108	Treatment implications of C9ORF72. **2012**, 4, 46	9
1107	Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. **2012**, 31, 581-91	29
1106	GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer's disease patients. **2013**, 33, 23-7	34
1105	Alteration in cell cycle-related proteins in lymphoblasts from carriers of the c.709-1G>A PGRN mutation associated with FTLD-TDP dementia. **2012**, 33, 429.e7-20	18
1104	New mutations in MAPT gene causing frontotemporal lobar degeneration: biochemical and structural characterization. **2012**, 33, 834.e1-6	21
1103	Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases. **2012**, 33, 1012.e11-24	76
1102	Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. **2012**, 33, 2506-20	81
1101	Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in southern Italy. **2012**, 33, 2948.e1-2948.e10	35
1100	The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim?. **2012**, 96, 190-207	97
1099	Primary progressive aphasia and Alzheimer's disease: brief history, recent evidence. **2012**, 12, 709-14	29
1098	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. **2012**, 135, 723-35	226
1097	Molecular analysis and biochemical classification of TDP-43 proteinopathy. **2012**, 135, 3380-91	75
1096	Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease. **2012**, 501, 63-78	7
1095	Frontotemporal Lobar Degeneration. **2012**, 724, 114-27	10
1094	Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. **2012**, 26, 841-70	91
1093	Genetics of frontotemporal lobar degeneration. **2012**, 3, 52	28

1092	Advances in understanding the molecular basis of frontotemporal dementia. **2012**, 8, 423-34	306
1091	Losing protein in the brain: the case of progranulin. **2012**, 1476, 172-82	21
1090	Intrafamilial clinical phenotypic heterogeneity with progranulin gene p.Glu498fs mutation. **2012**, 316, 189-90	13
1089	Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology. **2012**, 8, 131-42	54
1088	Frontotemporal lobar degeneration: new understanding brings new approaches. **2012**, 22, 83-97, viii	2
1087	Montreal Cognitive Assessment (MoCA): validation study for frontotemporal dementia. **2012**, 25, 146-54	49
1086	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. **2011**, 13, 38-50	450
1085	Progranulin regulates neuronal outgrowth independent of sortilin. **2012**, 7, 33	104
1084	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. **2012**, 7, e43099	35
1083	Mechanisms of loss of functions of human angiogenin variants implicated in amyotrophic lateral sclerosis. **2012**, 7, e32479	40
1082	Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12). **2012**, 7, e35115	77
1081	Inactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>A. **2012**, 7, e37057	11
1080	Widespread structural and functional connectivity changes in amyotrophic lateral sclerosis: insights from advanced neuroimaging research. **2012**, 2012, 473538	16
1079	Parkinson□ Disease: Insights from the Laboratory and Clinical Therapeutics. **2012**,	
1078	Alzheimer's disease and related dementias. 17-31	
1077	A Major Genetic Factor at Chromosome 9p Implicated in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). **2012**,	1
1076	Alzheimer's disease. 371-381	1
1075	Synucleinopathies and Tauopathies. **2012**, 829-843	4

1074	On the 'classification' of neurodegenerative disorders: discrete entities, overlap or continuum?. **2012**, 50, 201-8	21
1073	Genetics of Neurodegenerative Diseases. **2012**, 719-736	0
1072	RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. **2012**, 3, 265-85	36
1071	Differentiating the dementias: a neurological approach. **2012**, 16, 11-18	9
1070	A clinical approach to early-onset inheritable dementia. **2012**, 27, 154-61	16
1069	Frontotemporal dementia in elderly individuals. **2012**, 69, 1052-60	41
1068	New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration. **2012**, 12, 502-10	21
1067	Pallidopontonigral degeneration: a deceptive familial tauopathy. **2012**, 27, 817-9	4
1066	Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. **2012**, 228, 67-76	92
1065	Quantifying change in individual subjects affected by frontotemporal lobar degeneration using automated longitudinal MRI volumetry. **2012**, 33, 1526-35	22
1064	The non-fluent/agrammatic variant of primary progressive aphasia. **2012**, 11, 545-55	147
1063	Genetics of dementia: update and guidelines for the clinician. **2012**, 159B, 628-43	33
1062	Sortilin and SorLA regulate neuronal sorting of trophic and dementia-linked proteins. **2012**, 45, 379-87	16
1061	Clinical phenotypes and genetic biomarkers of FTLD. **2012**, 119, 851-60	16
1060	Prevalence of frontotemporal lobar degeneration in an isolated population: the Vallecamonica study. **2012**, 33, 899-904	17
1059	A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP). **2012**, 38, 25-38	15
1058	Neuroprotective effects of progranulin in ischemic mice. **2012**, 1436, 130-6	42
1057	Progranulin: an emerging target for FTLD therapies. **2012**, 1462, 118-28	33

1056	Progranulin contributes to endogenous mechanisms of pain defense after nerve injury in mice. **2012**, 16, 708-21	17
1055	Autosomal dominant Parkinson's disease in a large German pedigree. **2012**, 126, 129-37	1
1054	Core features of frontotemporal dementia recapitulated in progranulin knockout mice. **2012**, 45, 395-408	89
1053	Synaptic dysfunction in progranulin-deficient mice. **2012**, 45, 711-22	119
1052	MicroRNAs in neurodegenerative diseases and their therapeutic potential. **2012**, 133, 142-50	161
1051	Progranulin: a growth factor, a novel TNFR ligand and a drug target. **2012**, 133, 124-32	80
1050	An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. **2012**, 32, 505-14	99
1049	Progranulin genetic screening in frontotemporal lobar degeneration patients from central Italy. **2012**, 32, 13-6	9
1048	A progranulin mutation associated with cortico-basal syndrome in an Italian family expressing different phenotypes of fronto-temporal lobar degeneration. **2012**, 33, 93-7	10
1047	Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. **2013**, 33, 122-33	38
1046	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. **2013**, 1, 36	19
1045	Promoter DNA methylation regulates progranulin expression and is altered in FTLD. **2013**, 1, 16	35
1044	Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. **2013**, 79, 416-38	1038
1043	Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review. **2013**, 2, 8	37
1042	Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. **2013**, 126, 401-9	119
1041	Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. **2013**, 126, 39-50	20
1040	Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. **2013**, 125, 523-33	18
1039	Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. **2013**, 1530, 54-65	19

1038	TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update. **2013**, 34, 812-26	171
1037	Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. **2013**, 70, 1411-7	87
1036	The behavioral variant of frontotemporal dementia: linking neuropathology to social cognition. **2013**, 34, 1267-74	19
1035	Lysosomal storage disorders and iron. **2013**, 110, 251-75	7
1034	Behavioral and language variants of frontotemporal dementia: a review of key symptoms. **2013**, 115, 2405-10	22
1033	Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. **2013**, 1504, 16-24	35
1032	Genetic factors in frontotemporal dementia: A review. **2013**, 5, 113-130	2
1031	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. **2013**, 1, 68	131
1030	The growth factor progranulin attenuates neuronal injury induced by cerebral ischemia-reperfusion through the suppression of neutrophil recruitment. **2013**, 10, 105	96
1029	Genetics of amyotrophic lateral sclerosis: an update. **2013**, 8, 28	208
1028	Pathological assessments for the presence of hexanucleotide repeat expansions in C9ORF72 in Alzheimer's disease. **2013**, 1, 50	10
1027	Progranulin antibodies entertain a proinflammatory environment in a subgroup of patients with psoriatic arthritis. **2013**, 15, R211	35
1026	Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. **2013**, 169, 811-9	30
1025	Progranulin directly binds to the CRD2 and CRD3 of TNFR extracellular domains. **2013**, 587, 3428-36	60
1024	Progranulin peripheral levels as a screening tool for the identification of subjects with progranulin mutations in a Portuguese cohort. **2014**, 13, 214-23	22
1023	Early-onset dementias: diagnostic and etiological considerations. **2013**, 5, S7	30
1022	Exacerbated inflammatory responses related to activated microglia after traumatic brain injury in progranulin-deficient mice. **2013**, 231, 49-60	82
1021	Progranulin antibodies in autoimmune diseases. **2013**, 42, 29-38	51

1020	Progress in frontotemporal dementia research. **2013**, 28, 15-23	11
1019	Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese patients with FTLD, PSP, and CBS. **2013**, 19, 15-20	65
1018	Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington's disease models. **2013**, 22, 782-94	28
1017	Insights into the role of progranulin in immunity, infection, and inflammation. **2013**, 93, 199-208	140
1016	The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. **2013**, 22, 685-95	116
1015	[Frontotemporal dementias]. **2013**, 84, 20-32	11
1014	Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. **2013**, 34, 2890.e7-2890.e12	28
1013	The promotion of bone healing by progranulin, a downstream molecule of BMP-2, through interacting with TNF/TNFR signaling. **2013**, 34, 6412-21	80
1012	Translational proteomics in Alzheimer's disease and related disorders. **2013**, 46, 480-6	17
1011	Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice. **2013**, 250, 8-19	99
1010	Distinctive age-related temporal cortical thinning in asymptomatic granulin gene mutation carriers. **2013**, 34, 1462-8	14
1009	The clinical and pathological phenotypes of frontotemporal dementia with C9ORF72 mutations. **2013**, 335, 26-35	20
1008	Mechanisms of granulin deficiency: lessons from cellular and animal models. **2013**, 47, 337-60	49
1007	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. **2013**, 125, 413-23	250
1006	The changing scene of amyotrophic lateral sclerosis. **2013**, 14, 248-64	716
1005	Novel progranulin mutations with reduced serum-progranulin levels in frontotemporal lobar degeneration. **2013**, 21, 1260-5	6
1004	Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. **2013**, 19, 407-15	173
1003	Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship. **2013**, 19, 182-200	30

1002	Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease. **2013**, 5, 24	27
1001	Tau pathology and neurodegeneration. **2013**, 12, 609-22	698
1000	The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. **2013**, 34, 2541-7	50
999	Second cistron in CACNA1A gene encodes a transcription factor mediating cerebellar development and SCA6. **2013**, 154, 118-33	119
998	Molecular signature of disease onset in granulin mutation carriers: a gene expression analysis study. **2013**, 34, 1837-45	14
997	C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. **2013**, 126, 845-57	225
996	Novel progranulin variants do not disrupt progranulin secretion and cleavage. **2013**, 34, 2538-40	5
995	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. **2013**, 25, 210-20	11
994	Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. **2013**, 126, 545-54	22
993	Accurate Assessment of Behavioral Variant Frontotemporal Dementia. **2013**, 313-332	2
992	Consciousness and the Global Neuronal Workspace Hypothesis: From Bottom-Up to Top-Down Causation and Vice Versa. **2013**, 235-272	1
991	Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. **2013**, 70, 78-84	257
990	Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. **2013**, 136, 455-70	30
989	Deletion of progranulin exacerbates atherosclerosis in ApoE knockout mice. **2013**, 100, 125-33	64
988	A shift to organismal stress resistance in programmed cell death mutants. **2013**, 9, e1003714	31
987	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. **2013**, 81, 1322-31	45
986	Clinical and electrophysiologic variability in amyotrophic lateral sclerosis within a kindred harboring the C9ORF72 repeat expansion. **2013**, 14, 132-7	7
985	S6K2: The Neglected S6 Kinase Family Member. **2013**, 3, 191	40

984	TDP-43 frontotemporal lobar degeneration and autoimmune disease. **2013**, 84, 956-62	103
983	Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosis. **2013**, 80, 1771-7	19
982	Activity-dependent secretion of progranulin from synapses. **2013**, 126, 5412-21	35
981	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. **2013**, 22, R77-87	111
980	The genetics of dementia. **2013**, 33, 417-22	3
979	Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. **2013**, 81, 1945-52	78
978	Plasma progranulin levels in cortical dementia phenotypes with asymmetric perisylvian atrophy. **2013**, 20, 1319-24	4
977	TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. **2013**, 126, 781-91	57
976	CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. **2013**, 74, 39-52	75
975	Genomic editing opens new avenues for zebrafish as a model for neurodegeneration. **2013**, 127, 461-70	46
974	Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting. **2013**, 39, 335-47	8
973	Progranulin deficiency promotes post-ischemic blood-brain barrier disruption. **2013**, 33, 19579-89	63
972	The epidemiology of frontotemporal dementia. **2013**, 25, 130-7	280
971	Secreted progranulin is a homodimer and is not a component of high density lipoproteins (HDL). **2013**, 288, 8627-8635	12
970	GRN Thr272fs clinical heterogeneity: a case with atypical late onset presenting with a dementia with Lewy bodies phenotype. **2013**, 35, 669-74	13
969	Secretory leukocyte protease inhibitor protein regulates the penetrance of frontotemporal lobar degeneration in progranulin mutation carriers. **2014**, 38, 533-9	7
968	Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study. **2013**, 35, 313-8	13
967	Progranulin mutations as risk factors for Alzheimer disease. **2013**, 70, 774-8	84

966	Phenotypic variability of familial and sporadic Progranulin p.Gln257Profs*27 mutation. **2013**, 37, 335-42	8
965	Neurodegenerative disorders. 23-71	
964	Neuropathology of frontotemporal lobar degeneration: a review. **2013**, 7, 19-26	16
963	The role of the innate immune system in Alzheimer's disease and frontotemporal lobar degeneration: an eye on microglia. **2013**, 2013, 939786	22
962	Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia. **2013**, 36, 415-20	14
961	Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia. **2013**, 8, e72107	22
960	Learning and memory with neuropathic pain: impact of old age and progranulin deficiency. **2013**, 7, 174	17
959	Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. **2013**, 5, 6	69
958	Frontotemporal dementia and primary progressive aphasia, a review. **2014**, 10, 1045-55	35
957	Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease. **2014**, 9, e97032	46
956	Therapeutic and diagnostic challenges for frontotemporal dementia. **2014**, 6, 204	16
955	Genetic variants in diseases of the extrapyramidal system. **2014**, 15, 18-27	3
954	Three TNFR-binding domains of PGRN act independently in inhibition of TNF-alpha binding and activity. **2014**, 19, 1176-85	33
953	The role of PGRN in musculoskeletal development and disease. **2014**, 19, 662-71	15
952	Potential prognostic, diagnostic and therapeutic markers for human gastric cancer. **2014**, 20, 13791-803	14
951	Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta-analysis. **2015**, 43, 325-34	5
950	Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. **2014**, 94, 1224-36	2
949	Progranulin transcripts with short and long 5' untranslated regions (UTRs) are differentially expressed via posttranscriptional and translational repression. **2014**, 289, 25879-89	18

948	Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. **2014**, 35, 2485-94	13
947	Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers. **2014**, 71, 216-21	33
946	Peripheral progranulin levels do not reflect brain progranulin levels. **2014**, 9, 521-524	
945	Biomarkers in the primary progressive aphasias. **2014**, 28, 922-940	13
944	A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. **2014**, 40, 502-13	31
943	A solid-phase assay for studying direct binding of progranulin to TNFR and progranulin antagonism of TNF/TNFR interactions. **2014**, 1155, 163-72	19
942	Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. **2014**, 75, 116-26	181
941	Progranulin, a major secreted protein of mouse adipose-derived stem cells, inhibits light-induced retinal degeneration. **2014**, 3, 42-53	38
940	Frontotemporal dementia: diagnosis, deficits and management. **2014**, 4, 439-54	56
939	Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. **2014**, 2, 70	91
938	TMEM106B expression is reduced in Alzheimer's disease brains. **2014**, 6, 17	25
937	Genetics in degenerative dementia: current status and applicability. **2014**, 28, 199-205	12
936	A novel GRN mutation (GRN c.708+6_+9delTGAG) in frontotemporal lobar degeneration with TDP-43-positive inclusions: clinicopathologic report of 6 cases. **2014**, 73, 467-73	7
935	Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. **2014**, 23, 1467-78	71
934	Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43. **2014**, 289, 10769-10784	72
933	Frontotemporal lobar degeneration: current perspectives. **2014**, 10, 297-310	79
932	Early neuropsychological characteristics of progranulin mutation carriers. **2014**, 20, 694-703	15
931	Frontotemporal lobar degeneration: a clinical approach. **2014**, 34, 189-201	58

930	Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis. **2014**, 71, 172-9	23
929	Cortical degeneration in frontotemporal lobar degeneration with TDP-43 proteinopathy caused by progranulin gene mutation. **2014**, 124, 894-903	3
928	ALS-FTD complex disorder due to C9ORF72 gene mutation: description of first Polish family. **2014**, 72, 64-71	1
927	No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. **2014**, 40, 844-54	17
926	Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301L MAPT mutation: dysexecutive, aphasic, apraxic or spatial phenomenon?. **2014**, 20, 69-86	13
925	Diagnosis and management of behavioral variant frontotemporal dementia. **2014**, 75, 574-81	69
924	Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer's disease. **2014**, 542, 141-5	38
923	Clinical and genetic analysis of MAPT, GRN, and C9orf72 genes in Korean patients with frontotemporal dementia. **2014**, 35, 1213.e13-7	28
922	Genetics of dementia. **2014**, 383, 828-40	179
921	Progranulin-associated PiB-negative logopenic primary progressive aphasia. **2014**, 261, 604-14	48
920	C9ORF72: grabbing a tiger by the tail. **2014**, 127, 311-8	1
919	Mechanisms of toxicity in C9FTLD/ALS. **2014**, 127, 359-76	114
918	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. **2014**, 127, 397-406	108
917	Partial deletions of the GRN gene are a cause of frontotemporal lobar degeneration. **2014**, 15, 95-100	10
916	Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. **2014**, 49, 786-803	56
915	Neurodegenerative Diseases. **2014**,	2
914	Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. **2014**, 23, R47-53	48
913	Progranulin in neurodegenerative disease. **2014**, 37, 388-98	119

912	Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. **2014**, 137, 255-67	76
911	Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. **2014**, 127, 151-73	36
910	Motor neuron disease and frontotemporal dementia: sometimes related, sometimes not. **2014**, 262 Pt B, 75-83	63
909	TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?. **2014**, 20, 66-71	77
908	The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. **2014**, 28, 30-40	38
907	Dual cell protective mechanisms activated by differing levels of oxidative stress in HT22 murine hippocampal cells. **2014**, 78, 1495-503	6
906	MicroRNA-339-5p down-regulates protein expression of β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. **2014**, 289, 5184-98	119
905	Parkinsonian syndrome in familial frontotemporal dementia. **2014**, 20, 957-64	62
904	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. **2014**, 85, 684-91	47
903	Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. **2014**, 211, 1937-45	67
902	Progranulin protects against amyloid β deposition and toxicity in Alzheimer's disease mouse models. **2014**, 20, 1157-64	153
901	Significance and limitation of the pathological classification of TDP-43 proteinopathy. **2014**, 34, 578-88	20
900	Patterns of microglial cell activation in frontotemporal lobar degeneration. **2014**, 40, 686-96	50
899	Innate immune activation in neurodegenerative disease. **2014**, 14, 463-77	799
898	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. **2014**, 6, 1	110
897	Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. **2014**, 2, 78	101
896	Understanding the role of progranulin in Alzheimer's disease. **2014**, 20, 1099-100	7
895	Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. **2014**, 127, 845-60	135

894	Movement Disorders in Dementias. **2014**,	2
893	Movement Disorders. **2014**, 313-346	
892	Frontotemporal dementia and its subtypes: a genome-wide association study. **2014**, 13, 686-99	207
891	Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment. **2014**, 9, 117-32	11
890	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. **2014**, 35, 1473-82	38
889	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. **2014**, 35, 408-17	29
888	Dementia in a dish. **2014**, 75, 558-64	6
887	PGRN haploinsufficiency increased Wnt5a signaling in peripheral cells from frontotemporal lobar degeneration-progranulin mutation carriers. **2014**, 35, 886-98	20
886	Progranulin is required for proper ER stress response and inhibits ER stress-mediated apoptosis through TNFR2. **2014**, 26, 1539-48	37
885	Accumulation of C-terminal fragments of transactive response DNA-binding protein 43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. **2014**, 35, 79-87	32
884	Genome-wide association study in FTD: divide to conquer. **2014**, 13, 643-4	4
883	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. **2014**, 15, 344-50	55
882	Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. **2014**, 262 Pt B, 84-90	70
881	C9orf72; abnormal RNA expression is the key. **2014**, 262 Pt B, 102-10	13
880	Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. **2014**, 134, 364-71	25
879	Establishment of a surgically-induced model in mice to investigate the protective role of progranulin in osteoarthritis. **2014**, e50924	16
878	Effects of hypoxia on progranulin expression in HT22 mouse hippocampal cells. **2014**, 9, 1675-80	17
877	A mutation in the 5'-UTR of GRN gene associated with frontotemporal lobar degeneration: phenotypic variability and possible pathogenetic mechanisms. **2014**, 42, 939-47	8

876	Association of the variant Cys139Arg at GRN gene to the clinical spectrum of frontotemporal lobar degeneration. **2014**, 40, 679-85	8
875	Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. **2015**, 41, 858-81	130
874	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. **2016**, 50, 539-46	28
873	Possible involvement of the cerebellum in motor-function impairment in progranulin-deficient mice. **2015**, 26, 877-81	7
872	Progranulin Reduced Neuronal Cell Death by Activation of Sortilin 1 Signaling Pathways After Subarachnoid Hemorrhage in Rats. **2015**, 43, e304-e311	16
871	Histone deacetylases (HDACs) in frontotemporal lobar degeneration. **2015**, 41, 245-57	8
870	The genetic basis of amyotrophic lateral sclerosis: recent breakthroughs. **2015**, 327	10
869	The Genetics of Monogenic Frontotemporal Dementia. **2015**, 9, 219-229	28
868	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. **2015**, 7, 171	75
867	Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. **2015**, 9, 28	185
866	Neurodegeneration and Dementia. **2015**, 398-406	
865	Granulin knock out zebrafish lack frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis pathology. **2015**, 10, e0118956	16
864	The Evolution of the Secreted Regulatory Protein Progranulin. **2015**, 10, e0133749	37
863	Telling the Story of Frontotemporal Dementia by Bibliometric Analysis. **2015**, 48, 703-9	9
862	Frontotemporal Lobar Degeneration. **2015**, 57-66	1
861	Progranulin Deficiency Reduces CDK4/6/pRb Activation and Survival of Human Neuroblastoma SH-SY5Y Cells. **2015**, 52, 1714-1725	1
860	Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis. **2015**, 12, 340-51	23
859	Dominant frontotemporal dementia mutations in 140 cases of primary progressive aphasia and speech apraxia. **2015**, 39, 281-6	26

858	Right Temporal Lobe Atrophy: A Case That Initially Presented as Excessive Piety. **2015**, 29, 1053-67	9
857	The African Turquoise Killifish Genome Provides Insights into Evolution and Genetic Architecture of Lifespan. **2015**, 163, 1539-54	121
856	Granulin levels in patients with idiopathic premature ovarian failure. **2015**, 193, 108-10	2
855	Neuroepigenetics: Desoxyribonucleic acid methylation in Alzheimer's disease and other dementias. **2015**, 144, 457-464	
854	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. **2015**, 129, 469-91	165
853	Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72-a cautionary note. **2015**, 36, 1224-6	9
852	Small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. **2015**, 36, 1601.e1-5	17
851	Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. **2015**, 142, 45-53	38
850	Restoration of progranulin expression rescues cortical neuron generation in an induced pluripotent stem cell model of frontotemporal dementia. **2015**, 4, 16-24	51
849	Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. **2015**, 41, 24-46	275
848	Genetics and underlying pathology of dementia. **2015**, 25, 113-24	22
847	The role of neuroinflammation in dementias. **2015**, 15, 17	76
846	Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. **2015**, 22, 745-52	86
845	Genetic and Molecular Aspects of Frontotemporal Lobar Degeneration. **2015**, 3, 8-18	3
844	Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. **2015**, 262, 814-22	37
843	Dementia: An Overview of Risk Factors. **2015**, 187-198	4
842	Postmorbid learning of saxophone playing in a patient with frontotemporal dementia. **2015**, 21, 767-72	14
841	Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. **2015**, 49, 182-7	34

840	Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration. **2015**, 36, 1603.e1-4	22
839	Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. **2015**, 112, E3699-708	211
838	Profiling of ubiquitination pathway genes in peripheral cells from patients with frontotemporal dementia due to C9ORF72 and GRN mutations. **2015**, 16, 1385-94	9
837	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. **2015**, 36, 2904.e13-26	34
836	Genetics of Parkinson Disease and Related Diseases. **2015**, 769-778	0
835	p62/SQSTM1 analysis in frontotemporal lobar degeneration. **2015**, 36, 1603.e5-9	10
834	Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. **2015**, 11, 266-79	145
833	Increasing progranulin levels and blockade of the ERK1/2 pathway: upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia. **2015**, 25, 386-403	19
832	Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. **2015**, 16, 86-91	47
831	The Neuronal Ceroid-Lipofuscinoses (Batten Disease). **2015**, 793-808	5
830	TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. **2015**, 3, 15	29
829	Movement Disorder Genetics. **2015**,	
828	FTD and ALS--translating mouse studies into clinical trials. **2015**, 11, 360-6	55
827	A network of RNA and protein interactions in Fronto Temporal Dementia. **2015**, 8, 9	20
826	Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. **2015**, 130, 77-92	222
825	Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases. **2015**, 74, 380-7	26
824	Case records of the Massachusetts General Hospital. Case 9-2015. A 31-year-old man with personality changes and progressive neurologic decline. **2015**, 372, 1151-62	7
823	Focal Cortical Degenerations. **2015**, 707-711	

822	Rab8, POSH, and TAK1 regulate synaptic growth in a Drosophila model of frontotemporal dementia. **2015**, 208, 931-47	54
821	Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. **2015**, 74, 158-65	35
820	Psychiatric symptoms in frontotemporal dementia: epidemiology, phenotypes, and differential diagnosis. **2015**, 78, 684-92	52
819	Multiple therapeutic effects of progranulin on experimental acute ischaemic stroke. **2015**, 138, 1932-48	77
818	Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with α7 nicotinic acetylcholine receptor agonists. **2015**, 97, 454-462	12
817	Sortilin regulates progranulin action in castration-resistant prostate cancer cells. **2015**, 156, 58-70	26
816	Evaluation of maternal serum progranulin levels in normotensive pregnancies, and pregnancies with early- and late-onset preeclampsia. **2016**, 29, 2658-64	5
815	Neurogenetic disorders in the Basque population. **2015**, 79, 57-75	4
814	Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. **2015**, 16, 497-505	61
813	Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. **2015**, 130, 661-78	47
812	New discovery rarely runs smooth: an update on progranulin/TNFR interactions. **2015**, 6, 792-803	34
811	Genetics of Frontotemporal Dementia. **2015**, 75-105	
810	Decade in review-dementia: a decade of discovery and disappointment in dementia research. **2015**, 11, 613-4	3
809	How many biomarkers to discriminate neurodegenerative dementia?. **2015**, 52, 314-26	14
808	Update on Hippocampal Sclerosis. **2015**, 15, 67	20
807	Homozygous MAPT R406W mutation causing FTDP phenotype: A unique instance of a unique mutation. **2015**, 570, 150-2	6
806	NODding off in acute kidney injury with progranulin?. **2015**, 87, 873-5	4
805	Telling the tiger by its stripes: mapping the genomics of kidney graft tolerance in real time. **2015**, 87, 875-7	

804	Closing the tau loop: the missing tau mutation. **2015**, 138, 3100-9	29
803	Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. **2015**, 210, 991-1002	112
802	The molecular basis for development of proinflammatory autoantibodies to progranulin. **2015**, 61, 17-28	20
801	[Neuroepigenetics: Desoxyribonucleic acid methylation in Alzheimer's disease and other dementias]. **2015**, 144, 457-64	2
800	PGRN protects against colitis progression in mice in an IL-10 and TNFR2 dependent manner. **2014**, 4, 7023	46
799	Progranulin protects against osteoarthritis through interacting with TNF-□and □Catenin signalling. **2015**, 74, 2244-2253	93
798	Modelling Neurodegenerative Diseases Using Human Pluripotent Stem Cells. **2016**,	1
797	Heterogeneity of Parkinsonism in Familial Frontotemporal Dementia: Insights from Genetic Clues on the Pathogenesis. **2016**, 6,	
796	. **2016**,	6
795	Geneticsof frontotemporal dementia and related disorders. 185-196	
794	Primary progressive aphasia: conceptual evolution and challenges. **2016**, 9	6
793	Microglial Dysregulation in OCD, Tourette Syndrome, and PANDAS. **2016**, 2016, 8606057	51
792	Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: effects of genetic, demographic and neuropathological variables. **2016**, 54, 137-48	6
791	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. **2016**, 53, 107-16	5
790	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. **2016**, 8, 10	13
789	Commentary: Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. **2016**, 8, 11	3
788	Frontotemporal Lobar Degeneration and MicroRNAs. **2016**, 8, 17	16
787	Review: Induced pluripotent stem cell models of frontotemporal dementia. **2016**, 42, 497-520	7

786	Identification of biological pathways regulated by PGRN and GRN peptide treatments using transcriptome analysis. **2016**, 44, 2214-25	8
785	Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test. **2016**, 15, 588-603	22
784	Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. **2016**, 138 Suppl 1, 54-70	167
783	Targeting microglia for the treatment of Alzheimer's Disease. **2016**, 64, 1710-32	113
782	EphA2 is a functional receptor for the growth factor progranulin. **2016**, 215, 687-703	77
781	A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy. **2016**, 53, 475-85	9
780	Neuropathology offrontotemporal dementia and related disorders. 165-184	1
779	Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic. **2016**, 52, 1157-76	4
778	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. **2016**, 51, 277-91	13
777	Novel GRN Mutations in Patients with Corticobasal Syndrome. **2016**, 6, 22913	5
776	Mutational analysis of PRNP in Alzheimer's disease and frontotemporal dementia in China. **2016**, 6, 38435	14
775	Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 dependent manner. **2016**, 6, 21115	24
774	Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation. **2016**, 4, 74	15
773	Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. **2016**, 41, 200.e1-200.e5	73
772	Alzheimer disease: modeling an A□centered biological network. **2016**, 21, 861-71	36
771	"New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). **2016**, 75, 482-98	97
770	Fully reduced granulin-B is intrinsically disordered and displays concentration-dependent dynamics. **2016**, 29, 177-86	8
769	Extracellular matrix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulates chondrogenesis and endochondral ossification via associating with progranulin growth factor. **2016**, 30, 2741-54	10

768	Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. **2016**, 165, 921-35	378
767	Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. **2016**, 25, 2681-2697	38
766	Impaired protein degradation in FTLD and related disorders. **2016**, 32, 122-139	47
765	Serum Progranulin Levels in Type 2 Diabetic Patients with Metabolic Syndrome. **2016**, 54, 211-216	3
764	Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study. **2016**, 12, 460-5	31
763	Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals. **2016**, 84, 96-100	11
762	Trehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia. **2016**, 11, 46	65
761	The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death. **2016**, 291, 21448-21460	8
760	Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. **2016**, 22, 769-783	80
759	Prion-like propagation as a pathogenic principle in frontotemporal dementia. **2016**, 138 Suppl 1, 163-83	42
758	Programmed Cell Death During Caenorhabditis elegans Development. **2016**, 203, 1533-62	52
757	Genetics of FTLD: overview and what else we can expect from genetic studies. **2016**, 138 Suppl 1, 32-53	89
756	The clinical spectrum of sporadic and familial forms of frontotemporal dementia. **2016**, 138 Suppl 1, 6-31	78
755	Progranulin deficiency leads to severe inflammation, lung injury and cell death in a mouse model of endotoxic shock. **2016**, 20, 506-17	31
754	Charting Frontotemporal Dementia: From Genes to Networks. **2016**, 26, 16-27	7
753	C9orf72 binds SMCR8, localizes to lysosomes, and regulates mTORC1 signaling. **2016**, 27, 3040-3051	114
752	What we know about TMEM106B in neurodegeneration. **2016**, 132, 639-651	59
751	The role of progranulin in arthritis. **2016**, 1383, 5-20	39

750	Association Between Progranulin and Gaucher Disease. **2016**, 11, 127-137		53
749	Dementia and Cognitive Impairment. **2016**, 289-336		4
748	Genetics of Frontotemporal Dementia. **2016**, 16, 107		72
747	Prosaposin is a regulator of progranulin levels and oligomerization. **2016**, 7, 11992		49
746	Progranulin Controls Sepsis via C/EBP□Regulated Il10 Transcription and Ubiquitin Ligase/Proteasome-Mediated Protein Degradation. **2016**, 197, 3393-3405		17
745	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. **2016**, 3, 623-36		163
744	Progranulin overexpression in sensory neurons attenuates neuropathic pain in mice: Role of autophagy. **2016**, 96, 294-311		35
743	Targeting TDP-43 phosphorylation by Casein Kinase-1□inhibitors: a novel strategy for the treatment of frontotemporal dementia. **2016**, 11, 36		37
742	Biomedicine: A rare opportunity. *Nature*, **2016**, 537, S148-50	50.4	2
741	Analysis of large-scale whole exome sequencing data to determine the prevalence of genetically-distinct forms of neuronal ceroid lipofuscinosis. **2016**, 593, 284-91		19
740	Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia. **2016**, 533-546		1
739	Role of FET proteins in neurodegenerative disorders. **2016**, 13, 1089-1102		53
738	Progranulin Recruits HSP70 to □Glucocerebrosidase and Is Therapeutic Against Gaucher Disease. **2016**, 13, 212-224		62
737	Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers. **2016**, 6, 330-340		46
736	The Lysosome in Aging-Related Neurodegenerative Diseases. **2016**, 137-179		2
735	Poster Abstracts. **2016**, 36, 174-738		2
734	Progranulin and short-term outcome in patients with acute ischaemic stroke. **2016**, 23, 648-55		10
733	Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients. **2016**, 42, 35-40		14

732	Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis. **2016**, 22, 1007-12	10
731	Analyses MAPT, GRN, and C9orf72 mutations in Chinese patients with frontotemporal dementia. **2016**, 46, 235.e11-5	24
730	Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. **2016**, 38, 215.e1-215.e12	10
729	Asymmetric pathology in primary progressive aphasia with progranulin mutations and TDP inclusions. **2016**, 86, 627-36	24
728	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. **2016**, 123, 289-96	23
727	Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. **2016**, 139, 452-67	67
726	TDP-43 functions within a network of hnRNP proteins to inhibit the production of a truncated human SORT1 receptor. **2016**, 25, 534-45	52
725	The role of CHMP2B in autophagy and frontotemporal dementia. **2016**, 1649, 151-157	28
724	Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech. **2016**, 11, 90-98	8
723	C9orf72 is required for proper macrophage and microglial function in mice. **2016**, 351, 1324-9	334
722	Parkinsonism, movement disorders and genetics in frontotemporal dementia. **2016**, 12, 175-85	80
721	Practical Pharmacology for Alzheimer□ Disease. **2016**,	1
720	Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. **2016**, 315, 175-95	17
719	Basic Theory of Pharmacology for Alzheimer□ Disease. **2016**, 1-25	
718	Novel PSEN1 mutations (H214N and R220P) associated with familial Alzheimer's disease identified by targeted exome sequencing. **2016**, 40, 192.e7-192.e11	13
717	Loss of exosomes in progranulin-associated frontotemporal dementia. **2016**, 40, 41-49	40
716	Reduced secretion and altered proteolytic processing caused by missense mutations in progranulin. **2016**, 39, 220.e17-26	9
715	Increased Wnt Signaling and Reduced Viability in a Neuronal Model of Progranulin-Deficient Frontotemporal Lobar Degeneration. **2016**, 53, 7107-7118	7

714	Progranulin mutation analysis: Identification of one novel mutation in exon 12 associated with frontotemporal dementia. **2016**, 39, 218.e1-3	5
713	Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies. **2016**, 53, 6091-6105	9
712	The Role of PGRN in Alzheimer's Disease. **2016**, 53, 4189-4196	15
711	Early-onset Alzheimer's disease versus frontotemporal dementia: resolution with genetic diagnoses?. **2016**, 22, 161-7	2
710	Association analysis of the GRN´rs5848 and MAPT rs242557 polymorphisms in Parkinson's disease and multiple system atrophy: a large-scale population-based study and meta-analysis. **2016**, 126, 947-54	6
709	The Role of TDP-43 in Alzheimer's Disease. **2016**, 53, 3349-3359	44
708	The miR-15/107 Family of microRNA Genes Regulates CDK5R1/p35 with Implications for Alzheimer's Disease Pathogenesis. **2017**, 54, 4329-4342	60
707	Progranulin Protects Hippocampal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Immune Stress. **2017**, 54, 3717-3728	27
706	Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. **2017**, 27, 723-736	76
705	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. **2017**, 88, 152-164	76
704	Phase to Phase with TDP-43. **2017**, 56, 809-823	47
703	A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations. **2017**, 49, 219.e5-219.e13	4
702	Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. **2017**, 133, 785-807	50
701	The Receptor-interacting Serine/Threonine Protein Kinase 1 (RIPK1) Regulates Progranulin Levels. **2017**, 292, 3262-3272	11
700	Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. **2017**, 26, 969-988	84
699	Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. **2017**, 54, 145-154	57
698	Protein aggregation, misfolding and consequential human neurodegenerative diseases. **2017**, 127, 1047-1057	29
697	GRN deletion in familial frontotemporal dementia showing association with clinical variability in 3 familial cases. **2017**, 53, 193.e9-193.e16	8

696	Frontotemporal dementia. 143-155	
695	Glucose deprivation regulates the progranulin-sortilin axis in PC12 cells. **2017**, 7, 149-159	5
694	The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease. **2017**, 33, 877-890	18
693	Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. **2017**, 13, 858-869	18
692	C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease. **2017**, 18, 267-276	36
691	Frontotemporal Dementia. **2017**, 35, 339-374	177
690	Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. **2017**, 9,	107
689	Neuroinflammation as a therapeutic target in neurodegenerative diseases. **2017**, 49-80	4
688	Frontotemporal dementia. **2017**, 199-249	1
687	The perlecan-interacting growth factor progranulin regulates ubiquitination, sorting, and lysosomal degradation of sortilin. **2017**, 64, 27-39	18
686	Progranulin, lysosomal regulation and neurodegenerative disease. **2017**, 18, 325-333	114
685	Progranulin increases phagocytosis by retinal pigment epithelial cells in culture. **2017**, 95, 2500-2510	3
684	Accumulation of multiple neurodegenerative disease-related proteins in familial frontotemporal lobar degeneration associated with granulin mutation. **2017**, 7, 1513	25
683	Involvement of progranulin in modulating neuroinflammatory responses but not neurogenesis in the hippocampus of aged mice. **2017**, 95, 1-8	9
682	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. **2017**, 140, 1784-1791	31
681	Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo. **2017**, 26, 2850-2863	77
680	Microglial NFB-TNF hyperactivation induces obsessive-compulsive behavior in mouse models of progranulin-deficient frontotemporal dementia. **2017**, 114, 5029-5034	65
679	Imaging and fluid biomarkers in frontotemporal dementia. **2017**, 13, 406-419	104

678	Conditional loss of progranulin in neurons is not sufficient to cause neuronal ceroid lipofuscinosis-like neuropathology in mice. **2017**, 106, 14-22	12
677	New routes in frontotemporal dementia drug discovery. **2017**, 12, 659-671	5
676	Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. **2017**, 8, 15277	53
675	Muscle ceroid lipofuscin-like deposits in a patient with corticobasal syndrome due to a progranulin mutation. **2017**, 32, 1259-1260	2
674	Disulfide bonds and disorder in granulin-3: An unusual handshake between structural stability and plasticity. **2017**, 26, 1759-1772	10
673	Frontotemporal Dementia due to the Novel GRN Arg161GlyfsX36 Mutation. **2017**, 57, 1185-1189	3
672	Progranulin regulates neurogenesis in the developing vertebrate retina. **2017**, 77, 1114-1129	10
671	Formes g□□iques des d□□□escences lobaires frontotemporales´: o□en sommes-nous et o□ allons-nous ?. **2017**, 8, 106-110	
670	Restoring neuronal progranulin reverses deficits in a mouse model of frontotemporal dementia. **2017**, 140, 1447-1465	37
669	Potential skin involvement in ALS: revisiting Charcot's observation - a review of skin abnormalities in ALS. **2017**, 28, 551-572	10
668	Imbalance between TNF□and progranulin contributes to memory impairment and anxiety in sleep-deprived mice. **2017**, 7, 43594	14
667	Missense mutation in GRN gene affecting RNA splicing and plasma progranulin level in a family affected by frontotemporal lobar degeneration. **2017**, 54, 214.e1-214.e6	7
666	Foxo4- and Stat3-dependent IL-10 production by progranulin in regulatory T cells restrains inflammatory arthritis. **2017**, 31, 1354-1367	27
665	Molecular Genetics of Neurodegenerative Dementias. **2017**, 9,	28
664	Opening up the DNA methylome of dementia. **2017**, 22, 485-496	41
663	Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies. **2017**, 817, 76-85	5
662	Early clinical features of the parkinsonian-related dementias. 245-277	
661	Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. **2017**, 26, 4861-4872	61

660	Disease and Region Specificity of Granulin Immunopositivities in Alzheimer Disease and Frontotemporal Lobar Degeneration. **2017**, 76, 957-968	13
659	Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. **2017**, 140, 3081-3104	77
658	An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from gene mutations. **2017**, 3, 507-512	23
657	Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency. **2017**, 20, 2565-2574	65
656	Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis. **2017**, 89, 1633-1642	29
655	Modifiers of GRN-Associated Frontotemporal Lobar Degeneration. **2017**, 23, 962-979	17
654	Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons. **2017**, 363, 164-175	5
653	Homer, Spikar, and Other Drebrin-Binding Proteins in the Brain. **2017**, 1006, 249-268	5
652	Loss of synaptic zinc transport in progranulin deficient mice may contribute to progranulin-associated psychopathology and chronic pain. **2017**, 1863, 2727-2745	14
651	Protein Aggregation and Neurodegeneration: Tauopathies and Synucleinopathies. **2017**, 12-24	
650	Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. **2017**, 214, 2611-2628	70
649	Another piece in the progranulin puzzle: special binding between progranulin and prosaposin creates additional lysosomal access: An Editorial Comment for 'The interaction between progranulin and prosaposin is mediated by granulins and the linker region between saposin B and C' on page 236. **2017**, 143, 154-157	1
648	Amygdala TDP-43 Pathology in Frontotemporal Lobar Degeneration and Motor Neuron Disease. **2017**, 76, 800-812	10
647	Progranulin as a biomarker and potential therapeutic agent. **2017**, 22, 1557-1564	49
646	The interaction between progranulin and prosaposin is mediated by granulins and the linker region between saposin B and C. **2017**, 143, 236-243	17
645	A clinicopathological approach to the diagnosis of dementia. **2017**, 13, 457-476	138
644	Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinoma. **2017**, 17, 409	6
643	Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. **2017**, 5, 9	31

642	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. **2017**, 18, 112-119	44
641	Progranulin protects against exaggerated axonal injury and astrogliosis following traumatic brain injury. **2017**, 65, 278-292	45
640	ER stress and impaired autophagy flux in neuronal degeneration and brain injury. **2017**, 34, 3-14	88
639	Back to the tubule: microtubule dynamics in Parkinson's disease. **2017**, 74, 409-434	66
638	Tracking the development of agrammatic aphasia: A tensor-based morphometry study. **2017**, 90, 138-148	17
637	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia. **2017**, 17, 83-88	18
636	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. **2018**, 61, 753-760	18
635	Targeting Neuroinflammation to Treat Alzheimer's Disease. **2017**, 31, 1057-1082	129
634	Elevated progranulin contributes to synaptic and learning deficit due to loss of fragile X mental retardation protein. **2017**, 140, 3215-3232	15
633	Factors influencing the age at onset in familial frontotemporal lobar dementia: Important weight of genetics. **2017**, 3, e203	8
632	Genetic approaches to neurodegenerative disease. 57-76	
631	Animal models of dementia. 77-93	
630	Neuropathology of dementia. 94-122	1
629	Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke. **2017**, 24, 240-253	50
628	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. **2017**, 3, e201	2
627	Autophagy-Lysosome Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. **2017**,	1
626	. **2017**,	1
625	Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns. **2017**, 55, 185-192	8

624	Zinc as a Neuromodulator in the Central Nervous System with a Focus on the Olfactory Bulb. **2017**, 11, 297	35
623	Exosomes: Origins and Therapeutic Potential for Neurodegenerative Disease. **2017**, 11, 82	84
622	Wild-Type, but Not Mutant N296H, Human Tau Restores AÊMediated Inhibition of LTP in mice. **2017**, 11, 201	11
621	Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?. **2017**, 11, 672	21
620	Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum. **2017**, 10, 119	32
619	Relationships between Stress Granules, Oxidative Stress, and Neurodegenerative Diseases. **2017**, 2017, 1809592	59
618	Progranulin and Its Related MicroRNAs after Status Epilepticus: Possible Mechanisms of Neuroprotection. **2017**, 18,	6
617	Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer's disease. **2017**, 12, e0182896	25
616	A novel frameshift GRN mutation results in frontotemporal lobar degeneration with a distinct clinical phenotype in two siblings: case report and literature review. **2017**, 17, 182	6
615	Selective depletion of microglial progranulin in mice is not sufficient to cause neuronal ceroid lipofuscinosis or neuroinflammation. **2017**, 14, 225	17
614	The lysosomal protein cathepsin L is a progranulin protease. **2017**, 12, 55	54
613	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. **2017**, 5, 68	20
612	Frontotemporal Dementia. **2017**, 115-125	
611	Recent advances in the molecular genetics of frontotemporal lobar degeneration. **2017**, 32, 7-16	26
610	Structural magnetic resonance imaging in frontotemporal lobar dementia. **2017**, 15, 285-294	
609	Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by Mutations. **2017**, 4,	67
608	Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. **2018**, 115, E2849-E2858	27
607	Thalamic atrophy in frontotemporal dementia - Not just a problem. **2018**, 18, 675-681	28

606	Genetics of dementia in a Finnish cohort. **2018**, 26, 827-837	5
605	Frontotemporal dementia. **2018**, 148, 409-430	33
604	Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review. **2018**, 62, 1467-1480	36
603	Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. **2018**, 45, 1-17	16
602	Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts. **2018**, 233, 6524-6543	70
601	Lysosomes and Brain Health. **2018**, 41, 255-276	24
600	Targeting Alzheimer's disease with gene and cell therapies. **2018**, 284, 2-36	23
599	Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers. **2018**, 62, 583-589	3
598	Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration. **2018**, 62, 1683-1689	7
597	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. **2018**, 67, 84-94	13
596	Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. **2018**, 25, 648-662	38
595	Targeting Tyro3 ameliorates a model of PGRN-mutant FTLD-TDP via tau-mediated synaptic pathology. **2018**, 9, 433	15
594	Retrograde Signaling from Progranulin to Sort1 Counteracts Synapse Elimination in the Developing Cerebellum. **2018**, 97, 796-805.e5	20
593	Highly segregated localization of the functionally related vps10p receptors sortilin and SorCS2 during neurodevelopment. **2018**, 526, 1267-1286	6
592	Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease. **2018**, 28, 251-260	10
591	Neurotransmitter deficits from frontotemporal lobar degeneration. **2018**, 141, 1263-1285	77
590	Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis. **2018**, 38, 2341-2358	79
589	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. **2018**, 61, 1477-1483	6

588	Rest in peace FTDP-17. **2018**, 141, 324-331	5
587	Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis. **2018**, 137, 455-462	6
586	Genetic Modifiers in Neurodegeneration. **2018**, 6, 11-19	8
585	Genome-wide meta-analysis identifies novel determinants of circulating serum progranulin. **2018**, 27, 546-558	7
584	Progranulin: Functions and neurologic correlations. **2018**, 90, 118-125	7
583	The Effect of Predictive Testing in Adult-Onset Neurodegenerative Diseases on Social and Personal Life. **2018**, 27, 947-954	6
582	Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration. **2018**, 61, 1053-1060	3
581	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. **2018**, 141, 521-534	84
580	Autophagy and lysosomal pathways in nervous system disorders. **2018**, 91, 167-208	12
579	Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. **2018**, 10, 7	6
578	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice. **2018**, 67, 63-70	11
577	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. **2018**, 17, 548-558	60
576	Progranulin levels in blood in Alzheimer's disease and mild cognitive impairment. **2018**, 5, 616-629	14
575	Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer's Disease and Frontotemporal Dementia. **2018**, 62, 913-932	31
574	Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. **2018**, 66, 179.e17-179.e29	23
573	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. **2018**, 66, 181.e3-181.e10	12
572	Progranulin: A key player in autoimmune diseases. **2018**, 101, 48-55	59
571	Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (TAR DNA-binding protein 43 inclusions) in missense progranulin mutation Cys139Arg. **2018**, 28, 72-76	12

570	Prion-like Spreading in Tauopathies. **2018**, 83, 337-346	44
569	Angiogenin Prevents Progranulin A9D Mutation-Induced Neuronal-Like Cell Apoptosis Through Cleaving tRNAs into tiRNAs. **2018**, 55, 1338-1351	19
568	Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. **2018**, 181, 34-48	41
567	NG2/CSPG4 and progranulin in the posttraumatic glial scar. **2018**, 68-69, 571-588	32
566	Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. **2018**, 38, 72-81	21
565	Molecular mechanisms of the co-deposition of multiple pathological proteins in neurodegenerative diseases. **2018**, 38, 64-71	26
564	Neuroinflammation in Amyotrophic Lateral Sclerosis: Role of Redox (dys)Regulation. **2018**, 29, 15-36	24
563	Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia. **2018**, 62, 45-52	5
562	A Brazilian family with inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia linked to the VCP pGly97Glu mutation. **2018**, 37, 1129-1136	5
561	Frontotemporal dementia: latest evidence and clinical implications. **2018**, 8, 33-48	59
560	Atypical parkinsonian syndromes: a general neurologist's perspective. **2018**, 25, 41-58	27
559	Frequency of frontotemporal dementia gene variants in , , and in academic versus commercial laboratory cohorts. **2018**, 8, 23-33	3
558	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. **2018**, 10,	41
557	Disease-modifying effects of metabolic perturbations in ALS/FTLD. **2018**, 13, 63	18
556	Intrafamilial Phenotypic Variability in the Gene Expansion: 2 Case Studies. **2018**, 9, 1615	8
555	Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory diseases. **2018**, 19, 180	24
554	The identity and function of microglia in neurodegeneration. **2018**, 19, 1048-1058	134
553	A Druggable Genome Screen Identifies Modifiers of □Synuclein Levels via a Tiered Cross-Species Validation Approach. **2018**, 38, 9286-9301	21

552	Converging pathways in neurodegeneration, from genetics to mechanisms. **2018**, 21, 1300-1309	183
551	Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. **2018**, 13, 55	25
550	Progranulin Deficient Mice Develop Nephrogenic Diabetes Insipidus. **2018**, 9, 817-830	4
549	Progranulin in the hematopoietic compartment protects mice from atherosclerosis. **2018**, 277, 145-154	8
548	Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice. **2018**, 13, 48	39
547	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. **2018**, 13, e0197329	36
546	Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. **2018**, 5, 1163-1175	9
545	Monogenic inheritance in early-onset dementia: illustration in Alzheimer's disease and frontotemporal lobar dementia. **2018**, 16, 289-297	4
544	Traditional Mongolian medicine Eerdun Wurile improves stroke recovery through regulation of gene expression in rat brain. **2018**, 222, 249-260	11
543	Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration. **2018**, 173, 1073-1081	361
542	Genotype-phenotype links in frontotemporal lobar degeneration. **2018**, 14, 363-378	42
541	Alzheimer Disease and Frontotemporal Lobar Degeneration: Mouse Models. **2018**, 187-219	1
540	Gray matter changes in asymptomatic and mutation carriers. **2018**, 18, 591-598	16
539	Alzheimer's Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing. **2018**, 22, 505-513	24
538	Analysis of frontotemporal dementia, amyotrophic lateral sclerosis, and other dementia-related genes in 107 Korean patients with frontotemporal dementia. **2018**, 72, 186.e1-186.e7	20
537	Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. **2018**, 19, 497-506	16
536	Progranulin. **2018**,	
535	The Microglial Response to Neurodegenerative Disease. **2018**, 139, 1-50	12

534	A Brief Overview of Progranulin in Health and Disease. **2018**, 1806, 3-15	29
533	Methods to Investigate the Molecular Basis of Progranulin Actions on Brain and Behavior In Vivo Using Knockout Mice. **2018**, 1806, 233-253	1
532	Methods for Studying the Function of Progranulin in Atherosclerosis Using Both Knockout Mice Models and In Vitro Studies. **2018**, 1806, 315-328	1
531	Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. **2018**, 6, 42	14
530	Partial Tmem106b reduction does not correct abnormalities due to progranulin haploinsufficiency. **2018**, 13, 32	17
529	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. **2018**, 11, 2	67
528	Molecular Genetics of Frontotemporal Dementia Elucidated by Models-Defects in Endosomal?Lysosomal Pathway. **2018**, 19,	3
527	Targeted exome sequencing reveals homozygous TREM2 R47C mutation presenting with behavioral variant frontotemporal dementia without bone involvement. **2018**, 68, 160.e15-160.e19	12
526	The lysosomal function of progranulin,´a guardian against neurodegeneration. **2018**, 136, 1-17	87
525	Functional characterization of a novel progranulin mutation in a patient with progressive nonfluent aphasia. **2018**, 72, 186.e9-186.e12	2
524	WDR41 supports lysosomal response to changes in amino acid availability. **2018**, 29, 2213-2227	19
523	Pathogenic Signal Sequence Mutations in Progranulin Disrupt SRP Interactions Required for mRNA Stability. **2018**, 23, 2844-2851	19
522	Progranulin as a therapeutic target for dementia. **2018**, 22, 579-585	11
521	An Epigenetic Spin to ALS and FTD. **2018**, 20, 1-29	4
520	The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. **2019**, 45, 244-261	12
519	Age- and stress-associated C. elegans granulins impair lysosomal function and induce a compensatory HLH-30/TFEB transcriptional response. **2019**, 15, e1008295	11
518	FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology. **2019**, 78, 844-853	6
517	Neuroinflammation in frontotemporal dementia. **2019**, 15, 540-555	77

516	Progranulin deficiency leads to reduced glucocerebrosidase activity. **2019**, 14, e0212382	32
515	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. **2019**, 13, 757	14
514	Investigating the Conformational Response of the Sortilin Receptor upon Binding Endogenous Peptide- and Protein Ligands by HDX-MS. **2019**, 27, 1103-1113.e3	9
513	Progranulin and Frontotemporal Lobar Degeneration. **2019**, 35-69	2
512	Novel GRN mutations in Koreans with Alzheimer's disease. **2019**, 15, 345-352	3
511	FTD spectrum: Neuroimaging across the FTD spectrum. **2019**, 165, 187-223	10
510	TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment. **2019**, 67, 1873-1892	28
509	C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. **2019**, 7, 100	9
508	Soluble expression and purification of high-bioactivity recombinant human bone morphogenetic protein-2 by codon optimisation in Escherichia coli. **2019**, 32, 153-157	0
507	Suppression of Progranulin Expression Leads to Formation of Intranuclear TDP-43 Inclusions In Vitro: A Cell Model of Frontotemporal Lobar Degeneration. **2019**, 78, 1124-1129	1
506	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. **2019**, 6, 1782-1796	11
505	Frontotemporal dementia. **2019**, 165, 33-45	15
504	Generation of an induced pluripotent stem cell line (UBCi001-A) from a presymptomatic individual carrying the R418X progranulin gene mutation. **2019**, 41, 101582	1
503	Age-dependent emergence of neurophysiological and behavioral abnormalities in progranulin-deficient mice. **2019**, 11, 88	1
502	Predementia Brain Changes in Progranulin Mutation: A Systematic Review of Neuroimaging Evidence. **2019**, 47, 1-18	1
501	Emerging Role of Genetic Alterations Affecting Exosome Biology in Neurodegenerative Diseases. **2019**, 20,	15
500	RNA Granules Hitchhike on Lysosomes for Long-Distance Transport, Using Annexin A11 as a Molecular Tether. **2019**, 179, 147-164.e20	158
499	Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease. **2019**, 47, 4968-4980	9

498	The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. **2019**, 138, 751-770	34
497	Induction of PGRN by influenza virus inhibits the antiviral immune responses through downregulation of type I interferons signaling. **2019**, 15, e1008062	17
496	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. **2019**, 67, 1173-1179	3
495	Progranulin Stimulates the In Vitro Maturation of Pro-Cathepsin D at Acidic pH. **2019**, 431, 1038-1047	27
494	Abnormal TDP-43 function impairs activity-dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing. **2019**, 38,	8
493	Sex Differences in the Genetic Architecture of Alzheimer's Disease. **2019**, 7, 13-21	12
492	Genetic screen in a large series of patients with primary progressive aphasia. **2019**, 15, 553-560	19
491	Frontotemporal lobar degenerations: from basic science to clinical manifestations. **2019**, 45, 3-5	
490	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. **2019**, 9, 7803	16
489	Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. **2019**, 11,	2
488	Heterogeneous Nuclear Ribonucleoprotein E2 (hnRNP E2) Is a Component of TDP-43 Aggregates Specifically in the A and C Pathological Subtypes of Frontotemporal Lobar Degeneration. **2019**, 13, 551	10
487	Do Microglial Sex Differences Contribute to Sex Differences in Neurodegenerative Diseases?. **2019**, 25, 741-749	39
486	CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. **2019**, 6, 863-872	4
485	Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. **2019**, 11,	46
484	Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. **2019**, 13, 506	15
483	Multi-Granulin Domain Peptides Bind to Pro-Cathepsin D and Stimulate Its Enzymatic Activity More Effectively Than Progranulin in Vitro. **2019**, 58, 2670-2674	17
482	Granulin in Frontotemporal Lobar Degeneration: Molecular Mechanisms of the Disease. **2019**, 13, 395	6
481	Pleiotropic Protective Effects of Progranulin in the Treatment of Ischemic Stroke. **2019**, 157-167	1

480	Generation and Phenotyping of Progranulin-Deficient Mice. **2019**, 139-155	
479	Molecular and Functional Properties of Progranulin. **2019**, 1-17	
478	Confirmation of high frequency of C9orf72 mutations in patients with frontotemporal dementia from Sweden. **2019**, 84, 241.e21-241.e25	7
477	A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia. **2019**, 93, 269-283	14
476	Neural Stem/Progenitor Cells and Progranulin. **2019**, 127-138	
475	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. **2019**, 142, 1503-1527	454
474	Phagocytosis in the Brain: Homeostasis and Disease. **2019**, 10, 790	103
473	Neuronal ceroid lipofuscinosis type-11 in an adolescent. **2019**, 41, 542-545	16
472	Lysosomal dysfunction in proteinopathic neurodegenerative disorders: possible therapeutic roles of cAMP and zinc. **2019**, 12, 18	44
471	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. **2019**, 101, 1003-1015	18
470	Progranulin and Central Nervous System Disorders. **2019**,	
469	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. **2019**, 22, 101751	15
468	Variably protease-sensitive prionopathy: A differential diagnostic consideration for dementia. **2019**, 9, 145-151	3
467	Microglial Progranulin: Involvement in Alzheimer's Disease and Neurodegenerative Diseases. **2019**, 8,	24
466	In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier. **2019**, 6, 373-378	18
465	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. **2019**, 137, 901-918	21
464	A Highly Sensitive Sandwich ELISA to Detect CSF Progranulin: A Potential Biomarker for CNS Disorders. **2019**, 78, 406-415	2
463	Progranulin as a Potential Biomarker of Central Nervous System Disease. **2019**, 19-34	

462	Amygdala subnuclei are differentially affected in the different genetic and pathological forms of frontotemporal dementia. **2019**, 11, 136-141	11
461	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. **2019**, 137, 879-899	50
460	Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases. **2019**, 45, 53-64	30
459	Proximal recolonization by self-renewing microglia re-establishes microglial homeostasis in the adult mouse brain. **2019**, 17, e3000134	68
458	Recent advances in the genetics of frontotemporal dementia. **2019**, 7, 41-52	22
457	Viral Vector Therapeutics Against Alzheimer Disease. **2019**, 39-44	0
456	Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues. **2019**, 78, 98-110	31
455	Cysteine-rich granulin-3 rapidly promotes amyloid- fibrils in both redox states. **2019**, 476, 859-873	6
454	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. **2019**, 1118, 83-116	23
453	Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. **2019**, 431, 1818-1829	27
452	Preferential Disruption of Auditory Word Representations in Primary Progressive Aphasia With the Neuropathology of FTLD-TDP Type A. **2019**, 32, 46-53	11
451	Frontotemporal dementia. **2019**, 167, 279-299	9
450	Genetic mimics of the non-genetic atypical parkinsonian disorders - the 'atypical' atypical. **2019**, 149, 327-351	5
449	Parkinsonism in frontotemporal dementias. **2019**, 149, 249-275	15
448	Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology. **2019**, 7, 215	15
447	Impaired glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. **2019**, 7, 218	24
446	The Western Diet Regulates Hippocampal Microvascular Gene Expression: An Integrated Genomic Analyses in Female Mice. **2019**, 9, 19058	11
445	Synaptic Pruning by Microglia in Epilepsy. **2019**, 8,	24

444	Cross-Species Single-Cell Analysis Reveals Divergence of the Primate Microglia Program. **2019**, 179, 1609-1622.e16	355
443	Review: Modelling the pathology and behaviour of frontotemporal dementia. **2019**, 45, 58-80	9
442	AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity. **2019**, 27, 465-478	29
441	Peripheral GRN mRNA and Serum Progranulin Levels as a Potential Indicator for Both the Presence of Splice Site Mutations and Individuals at Risk for Frontotemporal Dementia. **2019**, 67, 159-167	7
440	Dedifferentiated Schwann cells secrete progranulin that enhances the survival and axon growth of motor neurons. **2019**, 67, 360-375	12
439	Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice. **2019**, 124, 152-162	6
438	Meta-analysis of Genetic Modifiers Reveals Candidate Dysregulated Pathways in Amyotrophic Lateral Sclerosis. **2019**, 396, A3-A20	11
437	Emerging new roles of the lysosome and neuronal ceroid lipofuscinoses. **2019**, 14, 4	43
436	RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration. **2019**, 14, 469-495	15
435	Review: Neuropathology of non-tau frontotemporal lobar degeneration. **2019**, 45, 19-40	57
434	Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. **2019**, 137, 71-88	20
433	Pathological Changes of Tau Related to Alzheimer's Disease. **2019**, 10, 931-944	29
432	Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets. **2020**, 98, 19-28	55
431	Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease. **2020**, 120, 901-906	4
430	Progranulin Regulates Inflammation and Tumor. **2020**, 19, 88-102	11
429	Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. **2020**, 29, 716-726	27
428	The missense p.Trp7Arg mutation in GRN gene leads to progranulin haploinsufficiency. **2020**, 85, 154.e9-154.e11	31
427	Progranulin deficiency confers resistance to autoimmune encephalomyelitis in mice. **2020**, 17, 1077-1091	7

426	Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure. **2020**, 86, 143-155	16
425	Coupling APEX labeling to imaging mass spectrometry of single organelles reveals heterogeneity in lysosomal protein turnover. **2020**, 219,	8
424	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. **2020**, 16, 22-36	19
423	Approaches to develop therapeutics to treat frontotemporal dementia. **2020**, 166, 107948	6
422	Frontotemporal dementia non-sense mutation of progranulin rescued by aminoglycosides. **2020**, 29, 624-634	8
421	Recent advances in the study of progranulin and its role in sepsis. **2020**, 79, 106090	2
420	Progranulin deficiency leads to enhanced age-related cardiac hypertrophy through complement C1q-induced □catenin activation. **2020**, 138, 197-211	4
419	Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms. **2020**, 143, 303-319	26
418	One novel GRN null mutation, two different aphasia phenotypes. **2020**, 87, 141.e9-141.e14	4
417	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. **2020**, 19, 145-156	90
416	International view on genetic frontotemporal dementia. **2020**, 19, 106-108	
415	Interaction between PGRN gene and the early trauma on clinical characteristics in patients with obsessive-compulsive disorder. **2020**, 263, 134-140	7
414	A transcriptomic analysis of Nsmce1 overexpression in mouse hippocampal neuronal cell by RNA sequencing. **2020**, 20, 459-470	2
413	The Progressive Supranuclear Palsy: Past and Present Aspects. **2020**, 43, 155-180	5
412	Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. **2020**, 46, 522-545	46
411	YB-1 Interferes with TNF□TNFR Binding and Modulates Progranulin-Mediated Inhibition of TNF□ Signaling. **2020**, 21,	2
410	Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. **2020**, 145, 105063	10
409	ALS Genetics: Gains, Losses, and Implications for Future Therapies. **2020**, 108, 822-842	72

408	The complex relationship between genotype, pathology and phenotype in familial dementia. **2020**, 145, 105082	1
407	Secreted Chaperones in Neurodegeneration. **2020**, 12, 268	11
406	The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire. **2020**, 78, 387-394	1
405	Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. **2020**, 8, 163	13
404	Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force. **2020**, 55, 45-68	70
403	Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. **2020**, 15, 40	165
402	Serum progranulin levels in paediatric patients with Gaucher disease; relation to disease severity and liver stiffness by transient elastography. **2020**, 40, 3051-3060	1
401	Elevated levels of extracellular vesicles in progranulin-deficient mice and FTD-GRN Patients. **2020**, 7, 2433-2449	4
400	Longitudinal Characterization of Transcriptomic, Functional, and Morphological Features in Human iPSC-Derived Neurons and Their Application to Investigate Translational Progranulin Disease Biology. **2020**, 12, 576678	1
399	Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. *Nature*, **2020**, 588, 459-465.	38
398	The neuronal ceroid-lipofuscinoses (Batten disease). **2020**, 53-71	1
397	The utility of whole exome sequencing for identification of the molecular etiology in autosomal recessive developmental and epileptic encephalopathies. **2020**, 41, 3729-3739	3
396	Prion-Like Propagation Mechanisms in Tauopathies and Traumatic Brain Injury: Challenges and Prospects. **2020**, 10,	2
395	Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer's Disease Genetics. **2020**, 43, 965-979	24
394	Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. **2020**, 109, 103553	8
393	Serum progranulin levels are associated with frailty in middle-aged individuals. **2020**, 15, e0238877	2
392	Isolation and characterization of antibody fragments selective for human FTD brain derived TDP-43 variants. **2020**, 21, 36	2
391	Discovery of small molecules that normalize the transcriptome and enhance cysteine cathepsin activity in progranulin-deficient microglia. **2020**, 10, 13688	4

390	Progranulin Adsorbs to Polypropylene Tubes and Disrupts Functional Assays: Implications for Research, Biomarker Studies, and Therapeutics. **2020**, 14, 602235	1
389	Female sex mitigates motor and behavioural phenotypes in TDP-43 knock-in mice. **2020**, 10, 19220	2
388	Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes. **2020**, 76, 341-347	5
387	Microglia and Wnt Pathways: Prospects for Inflammation in Alzheimer's Disease. **2020**, 12, 110	17
386	Variability of clinical syndromes and cerebral glucose metabolism in symptomatic frontotemporal lobar degeneration associated with progranulin mutations. **2020**, 21, 389-395	1
385	Loss of TMEM106B leads to myelination deficits: implications for frontotemporal dementia treatment strategies. **2020**, 143, 1905-1919	14
384	Progranulin Improves Acute Lung Injury through Regulating the Differentiation of Regulatory T Cells and Interleukin-10 Immunomodulation to Promote Macrophage Polarization. **2020**, 2020, 9704327	5
383	Lipotoxic Injury Differentially Regulates Brain Microvascular Gene Expression in Male Mice. **2020**, 12,	4
382	Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology. **2020**, 107, 496-508.e6	12
381	Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. **2020**, 15, 21	8
380	CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis. **2020**, 143, 783-799	33
379	Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. **2020**, 40, 426-435	8
378	The FTLD Risk Factor TMEM106B Regulates the Transport of Lysosomes at the Axon Initial Segment of Motoneurons. **2020**, 30, 3506-3519.e6	19
377	Impairment of Lysosome Function and Autophagy in Rare Neurodegenerative Diseases. **2020**, 432, 2714-2734	23
376	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. **2020**, 11, 80	6
375	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. **2020**, 91, 167.e1-167.e9	10
374	Multifaceted Genes in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia. **2020**, 14, 684	10
373	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. **2020**, 9, 27	10

372	Genetically programmed changes in transcription of the novel progranulin regulator. **2020**, 98, 1139-1148	1
371	Granulins Regulate Aging Kinetics in the Adult Zebrafish Telencephalon. **2020**, 9,	4
370	Genetic architecture of neurodegenerative dementias. **2020**, 168, 108014	3
369	Basal forebrain atrophy in frontotemporal dementia. **2020**, 26, 102210	7
368	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. **2020**, 20, 421-441	19
367	Genetic Diversity in Frontotemporal Dementia. **2020**, 54, 13-23	5
366	Pathomechanism Heterogeneity in the Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Disease Spectrum: Providing Focus Through the Lens of Autophagy. **2020**, 432, 2692-2713	11
365	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. **2020**, 88, 42-50	9
364	Progranulin suppresses the age-dependent enhancement of neuronal activity in the hypothalamus. **2020**, 720, 134755	
363	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. **2020**, 16, 118-130	25
362	Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. **2020**, 16, 60-70	17
361	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. **2020**, 16, 71-78	21
360	TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy. **2019**, 11, 376	9
359	Does hyperglycemia downregulate glucose transporters in the brain?. **2020**, 139, 109614	7
358	Experimental gene therapies for the NCLs. **2020**, 1866, 165772	5
357	Frontotemporal Dementia: Neuropathology, Genetics, Neuroimaging, and Treatments. **2020**, 43, 331-344	10
356	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. **2020**, 26, 769-780	226
355	Convulsive responses to seizure-inducible drugs are exacerbated in progranulin-deficient mice. **2020**, 31, 478-483	1

354	Genetic forms of frontotemporal lobar degeneration: Current diagnostic approach and new directions in therapeutic strategies. **2020**, 176, 571-581	6
353	Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the axis in mouse hippocampal neuronal cells. **2020**, 318, C1123-C1135	5
352	Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. **2021**, 157, 334-350	16
351	Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology. **2021**, 1281, 219-242	4
350	Transcriptomics analysis for the identification of potential age-related genes and cells associated with three major urogenital cancers. **2021**, 11, 641	0
349	Frontotemporal Dementia: A Cross-Cultural Perspective. **2021**, 1281, 141-150	2
348	Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. **2021**, 17, e1009224	10
347	Frontotemporal Lobar Degeneration. **2021**, 61-89	
346	Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. **2021**, 141, 327-339	13
345	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.. **2021**, 144, 3710-3726	3
344	Nosology of Primary Progressive Aphasia and the Neuropathology of Language. **2021**, 1281, 33-49	4
343	Clinical overview and phenomenology of movement disorders. **2021**, 1-51.e27	0
342	Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations. **2021**, 1281, 77-92	0
341	Reply: Two heterozygous progranulin mutations in progressive supranuclear palsy. **2021**, 144, e28	
340	Differential regulation of progranulin derived granulin peptides.	1
339	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. **2021**, 79, 1195-1201	5
338	CRISPR/Cas9-mediated grna gene knockout leads to neurodevelopmental defects and motor behavior changes in zebrafish. **2021**, 157, 520-531	3
337	Outcomes of Progranulin Gene Therapy in the Retina are Dependent on Time of Delivery.	

336	Copper toxicity of inflection point in human intestinal cell line Caco-2 dissected: influence of temporal expression patterns. **2021**, 57, 359-371	2
335	C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. **2021**, 17, 3306-3322	11
334	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. **2021**, 23, 1-24	3
333	Genetics of frontotemporal dementia in China. **2021**, 22, 321-335	4
332	The role of macrophage scavenger receptor 1 (Msr1) in prion pathogenesis. **2021**, 99, 877-887	2
331	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. **2021**, 27, 212-222	1
330	The Role of Microglia in Inherited White-Matter Disorders and Connections to Frontotemporal Dementia. **2021**, 14, 195-207	3
329	Molecular Basis of Neuronal Autophagy in Ageing: Insights from. **2021**, 10,	5
328	The Role of White Matter Dysfunction and Leukoencephalopathy/Leukodystrophy Genes in the Aetiology of Frontotemporal Dementias: Implications for Novel Approaches to Therapeutics. **2021**, 22,	2
327	Surf4 Promotes Endoplasmic Reticulum Exit of the Lysosomal Prosaposin-Progranulin Complex.	
326	Ist die Expression des GP88-Proteins (Progranulin) ein klinisch relevanter Prognosefaktor f Prostatakarzinompatienten?. **2021**, 28, 21-24	
325	Genetic disruption of WASHC4 drives endo-lysosomal dysfunction and cognitive-movement impairments in mice and humans. **2021**, 10,	7
324	Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration. **2021**, 13, 359-376	2
323	A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses.	
322	Neuropathological and behavioral characterization of aged Grn R493X progranulin-deficient frontotemporal dementia knockin mice. **2021**, 9, 57	2
321	Structural insight into mutations at 155 position of valosin containing protein (VCP) linked to inclusion body myopathy with Paget disease of bone and frontotemporal Dementia. **2021**, 28, 2128-2138	
320	Autoantibodies against Progranulin and IL-1 receptor antagonist in critically ill COVID-19.	1
319	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. **2021**, 151, 105247	1

318	Whole-Exome Sequencing and C9orf72 Analysis in Primary Progressive Aphasia. **2021**, 80, 985-990	3
317	Association of Hemoglobin A1C With TDP-43 Pathology in Community-Based Elders. **2021**,	0
316	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. **2021**, 96, e2296-e2312	12
315	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. **2021**, 89, 825-835	3
314	Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency. **2021**, 14, 676478	2
313	Progranulin in neurodegenerative dementia. **2021**, 158, 119-137	4
312	Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. **2021**, 47, 1050-1059	3
311	Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up. **2021**, 11, 10837	2
310	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. **2021**, 12, 679927	1
309	Chemical and genetic rescue of in vivo progranulin-deficient lysosomal and autophagic defects. **2021**, 118,	1
308	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. **2021**, 12, 3452	10
307	A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses. **2021**, 4,	3
306	Human progranulin-expressing mice as a novel tool for the development of progranulin-modulating therapeutics. **2021**, 153, 105314	2
305	C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. **2021**, 109, 2275-2291.e8	15
304	Hydrogen peroxide induces progranulin expression to control neurite outgrowth in HT22 cells. **2021**, 85, 2103-2112	0
303	Progranulin deficiency in Iba-1 myeloid cells exacerbates choroidal neovascularization by perturbation of lysosomal function and abnormal inflammation. **2021**, 18, 164	4
302	Diverse human astrocyte and microglial transcriptional responses to Alzheimer□ pathology.	0
301	Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. **2021**, 154, 105360	27

300	Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities. **2021**, 14, 713031	3
299	Neuronal VCP loss of function recapitulates FTLD-TDP pathology. **2021**, 36, 109399	5
298	Loss of TREM2 reduces hyperactivation of progranulin deficient microglia but not lysosomal pathology.	1
297	FTLD Patient-Derived Fibroblasts Show Defective Mitochondrial Function and Accumulation of p62. **2021**, 58, 5438-5458	1
296	TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. **2021**, 22,	4
295	AZP2006, a new promising treatment for Alzheimer's and related diseases. **2021**, 11, 16806	2
294	Single-cell multimodal analysis in a case with reduced penetrance of Progranulin-Frontotemporal Dementia. **2021**, 9, 132	1
293	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. **2021**,	0
292	Progranulin associates with Rab2 and is involved in autophagosome-lysosome fusion in Gaucher disease. **2021**, 99, 1639-1654	1
291	Processing of progranulin into granulins involves multiple lysosomal proteases and is affected in frontotemporal lobar degeneration. **2021**, 16, 51	4
290	Deciphering Neurodegenerative Diseases Using Long-Read Sequencing. **2021**, 97, 423-433	1
289	The spectrum of neurodevelopmental, neuromuscular and neurodegenerative disorders due to defective autophagy. **2021**, 1-22	2
288	Plasma NfL levels and longitudinal change rates in and -associated diseases: from tailored references to clinical applications. **2021**, 92, 1278-1288	2
287	Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. **2021**, 4, 961	1
286	Loss of Lysosomal Proteins Progranulin and Prosaposin Associated with Increased Neurofibrillary Tangle Development in Alzheimer Disease. **2021**, 80, 741-753	1
285	Mice Treated Subcutaneously with Mouse LPS-Converted PrP or LPS Alone Showed Brain Gene Expression Profiles Characteristic of Prion Disease. **2021**, 8,	
284	Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics?. **2021**, 22,	1
283	Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. **2021**, 184, 4651-4668.e25	11

282	Molecular targets and approaches to restore autophagy and lysosomal capacity in neurodegenerative disorders. **2021**, 82, 101018	1
281	Outcomes of progranulin gene therapy in the retina are dependent on time and route of delivery. **2021**, 22, 40-51	1
280	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial. **2021**, 4, e2125584	2
279	Delivering progranulin to neuronal lysosomes protects against excitotoxicity. **2021**, 297, 100993	5
278	Progranulin deficiency results in reduced bis(monoacylglycero)phosphate (BMP) levels and gangliosidosis.	0
277	Genetic variants in progranulin upstream open reading frames increase downstream protein expression. **2021**, 110, 113-113	
276	Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology.	
275	Genotyping and Plasma/Cerebrospinal Fluid Profiling of a Cohort of Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Patients. **2021**, 11,	0
274	Abnormal spatiotemporal expression pattern of progranulin and neurodevelopment impairment in VPA-induced ASD rat model. **2021**, 196, 108689	3
273	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. **2021**, 108, 155-167	0
272	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. **2021**, 11, 451	0
271	Frequency of frontotemporal dementia-related gene variants in Turkey. **2021**, 106, 332.e1-332.e11	
270	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. **2021**, 175, 42-55	1
269	Younger-Onset Dementias: Behavioral Neurology/Brain Diseases/Healthy & Pathological Aging. **2022**, 88-96	
268	Fluid Biomarkers of Frontotemporal Lobar Degeneration. **2021**, 1281, 123-139	1
267	FDG-PET in presymptomatic C9orf72 mutation carriers. **2021**, 31, 102687	2
266	Disease-related cortical thinning in presymptomatic granulin mutation carriers. **2021**, 29, 102540	2
265	Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. **2021**, 14, 16	5

264	Knowledge assessment and psychological impact of genetic counseling in people at risk for familial FTD. **2021**, 13, e12225	1
263	Single-cell deconvolution of 3,000 post-mortem brain samples for eQTL and GWAS dissection in mental disorders.	4
262	TDP-43 y su incidencia en demencias degenerativas. **2021**, 13, 37-47	
261	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. **2021**, 144, 2798-2811	2
260	Molecular Genetics of Frontotemporal Dementia.	2
259	Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17. 110-134	20
258	Frontotemporal Lobar Degeneration with TDP-43 Pathology. 393-403	1
257	Neuropsychology of Movement Disorders and Motor Neuron Disease. **2010**, 315-333	2
256	Animal Models of Amyotrophic Lateral Sclerosis. **2011**, 515-531	1
255	The Ubiquitin System in Alzheimer's Disease. **2020**, 1233, 195-221	25
254	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2017**, 147-191	2
253	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer disease. **2020**, 469-504	3
252	The Dementias. **2008**, 1855-1907	1
251	Disorders of Upper and Lower Motor Neurons. **2008**, 2183-2220	3
250	Disorders of Upper and Lower Motor Neurons. **2012**, 1855-1889	1
249	Increased cerebrospinal fluid progranulin correlates with interleukin-6 in the acute phase of neuromyelitis optica spectrum disorder. **2017**, 305, 175-181	17
248	Genetic architecture of common non-Alzheimer's disease dementias. **2020**, 142, 104946	16
247	Evidence for sortilin modulating regional accumulation of human tau prions in transgenic mice. **2017**, 114, E11029-E11036	13

246	Genome-wide association studies of brain structure and function in the UK Biobank.	9
245	miRNA biomarkers for diagnosis of ALS and FTD, developed by a nonlinear machine learning approach.	2
244	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.	1
243	Gene expression imputation provides insight into the genetic architecture of frontotemporal dementia.	0
242	Activated iPSC-microglia from C9orf72 ALS/FTD patients exhibit endosomal-lysosomal dysfunction.	4
241	C. elegansgranulins promote an age-associated decline in protein homeostasis via lysosomal protease inhibition.	1
240	A Mac2-positive progenitor-like microglial population survives independent of CSF1R signaling in adult mouse brain.	6
239	Galantamine in frontotemporal dementia and primary progressive aphasia. **2008**, 25, 178-85	135
238	Progranulin prevents regulatory NK cell cytotoxicity against antiviral T cells. **2019**, 4,	4
237	Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. **2012**, 122, 3955-9	198
236	Thinking laterally about neurodegenerative proteinopathies. **2013**, 123, 1847-55	80
235	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. **2020**, 8, 5	15
234	Ageing and dementia. **2008**, 1031-1152	5
233	Lack of estrogen receptor in astrocytes of progranulin-deficient mice. **2016**, 62, 547-551	3
232	Alteration in anxiety with relation to the volume of the locus ceruleus in progranulin-deficient mice. **2009**, 55, 518-22	17
231	The Effects of Progranulin in a Rat Model of Acute Myocardial Ischemia/Reperfusion are Mediated by Activation of the P13K/Akt Signaling Pathway. **2019**, 25, 229-237	4
230	Developmental synapse remodeling in the cerebellum and visual thalamus. **2019**, 8,	15
229	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. **2017**, 13, e1007045	19

228	Variation at GRN 3'-UTR rs5848 is not associated with a risk of frontotemporal lobar degeneration in Dutch population. **2009**, 4, e7494	20
227	Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). **2010**, 5, e9872	170
226	Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. **2011**, 6, e22850	73
225	Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: a novel mouse model. **2013**, 8, e64989	38
224	Cognitive reserve in granulin-related frontotemporal dementia: from preclinical to clinical stages. **2013**, 8, e74762	22
223	Progranulin protects vascular endothelium against atherosclerotic inflammatory reaction via Akt/eNOS and nuclear factor-Ƀ pathways. **2013**, 8, e76679	45
222	Evidence of the innate antiviral and neuroprotective properties of progranulin. **2014**, 9, e98184	13
221	Multimodal FMRI resting-state functional connectivity in granulin mutations: the case of fronto-parietal dementia. **2014**, 9, e106500	44
220	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. **2016**, 11, e0153852	17
219	Neurotrophic effects of progranulin in vivo in reversing motor neuron defects caused by over or under expression of TDP-43 or FUS. **2017**, 12, e0174784	14
218	New perspective on parkinsonism in frontotemporal lobar degeneration. **2013**, 6, 1-8	21
217	Progranulin deficiency induces overactivation of WNT5A expression via TNF-⍺NF-Ƀ pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers. **2016**, 41, 225-39	24
216	Effects of Exercise on Progranulin Levels and Gliosis in Progranulin-Insufficient Mice. **2015**, 2,	5
215	Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. **2020**, 21, e50219	22
214	Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice. **2020**, 21, e50241	17
213	Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. **2016**, 7, 39980-39995	20
212	Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. **2019**, 2,	13
211	Role of tau in Alzheimer's dementia and other neurodegenerative diseases. **2007**, 5, 1-12	3

210	Primary phagocytosis of neurons by inflamed microglia: potential roles in neurodegeneration. **2012**, 3, 27	97
209	tRNA cleavage: a new insight. **2020**, 15, 47-52	21
208	Modeling ALS and FTLD proteinopathies in yeast: An efficient approach for studying protein aggregation and toxicity. **2011**, 5, 250-257	11
207	Umbilical cord blood mesenchymal stem cells protect amyloid-β42 neurotoxicity via paracrine. **2012**, 4, 110-6	22
206	ESCRT, autophagy, and frontotemporal dementia. **2008**, 41, 827-32	21
205	A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain. **2020**, 9,	22
204	Current and Future Prospects for Gene Therapy for Rare Genetic Diseases Affecting the Brain and Spinal Cord. **2021**, 14, 695937	6
203	Microglia regulate brain progranulin levels through the endocytosis/lysosomal pathway. **2021**, 6,	2
202	Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions.	
201	Systems biology approaches to unravel the molecular and genetic architecture of Alzheimer's disease and related tauopathies. **2021**, 160, 105530	1
200	Genetik psychischer Störungen. **2008**, 71-108	
199	The Molecular and Genetic Basis of Neurodegenerative Diseases. **2009**, 2039-2068	
198	Frontal Lobe Disorders: Frontotemporal Dementia (Pick Disease).	
197	Leitliniensynopse zur S3-Leitlinie »Demenzen« (November 2009). **2010**, 125-226	
196	Klinik der Demenzen. **2010**, 60-76	1
195	AD-FTLD Spectrum: New Understanding of the Neurodegenerative Process from the Study of Risk Genes. **2010**, 235-246	
194	Frontotemporal Dementia-Parkinsonism. **2010**, 506-513	
193	Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. **2010**, 24, 4639-4647	11

192	Animal Models of Frontotemporal Dementia. **2011**, 533-547	
191	Pathological Validation of Animal Models of Dementia. **2011**, 99-141	
190	The Frontotemporal Dementia Syndromes. **2010**, 348-359	
189	Genetik bei psychischen Erkrankungen. **2011**, 127-165	
188	Clinical Spectrum of VCP Myopathy, Paget Disease, and fronTotemporal Dementia: Experimental Models and Potential Treatments. 219-229	
187	Nicht-Alzheimer-Demenzen. **2012**, 209-222	
186	Language and Speech Disorders. **2012**, 131-148	
185	Frontotemporal dementias. **2012**, 344-350	
184	De la maladie de Pick aux d□hences fronto-temporales. **2012**, 196, 431-443	
183	Alzheimer□ Disease and Frontotemporal Lobar Degeneration: Mouse Models. **2014**, 111-129	
182	Frontotemporal Lobar Degeneration: Genetics and Clinical Phenotypes. **2014**, 93-109	
181	Movement Disorders in Frontotemporal Dementia. **2014**, 141-153	
180	A Voxel Based Morphometric Analysis of Longitudinal Cortical Gray Matter Changes in Progranulin Mutation Carriers At-Risk for Frontotemporal Dementia: Preliminary Study. **2015**, 14, 163	2
179	Fractal Analysis in Neurodegenerative Diseases. **2016**, 233-249	0
178	Multiple therapeutic effects of a growth factor, progranulin on ischemic brain injury. **2016**, 27, 265-269	
177	Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2016**, 1-45	
176	Frontotemporal Dementia and Parkinsonism. **2017**,	
175	Frontotemporal Dementia. **2017**, 141-175	

174 Genetik und Gen-Umwelt-Interaktionen bei psychischen Erkrankungen. **2017**, 1-45

173 Translational research that enables inhibition of hemorrhagic transformation after tPA treatment for ischemic stroke. **2018**, 30, 11-15

172 Neuropsychologische aspecten van neurodegeneratieve aandoeningen. **2018**, 423-470

171 Solving the Puzzle of Neurodegeneration. **2018**, 1-22 0

170 Autosomal Dominant Frontotemporal Lobar Degeneration: From Genotype to Phenotype. **2018**, 123-145

169 AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T cell-mediated hippocampal degeneration.

168 Unaltered prion disease in mice lacking developmental endothelial locus-1 (Del-1).

167 Nemo-like kinase regulates Progranulin levels in the brain through the microglial endocytosis-lysosomal pathway.

166 Investigating the conformational response of the Sortilin receptor upon binding endogenous peptide- and protein ligands by HDX-MS.

165 Progranulin Regulations of Lysosomal Homeostasis and Its Involvement in Neurodegenerative Diseases. **2019**, 85-103

164 Progranulin in Sexual Differentiation of the Developing Brain. **2019**, 105-116

163 Neuropsychology of Movement Disorders and Motor Neuron Disease: Parkinson Disease, Progressive Supranuclear Palsy, Essential Tremor, Huntington Disease, and Amyotrophic Lateral Sclerosis. **2019**, 415-440

162 PGRN and Neurodegenerative Diseases Other Than FTLD. **2019**, 71-84

161 Assessment of Behavioral Variant Frontotemporal Dementia. **2019**, 523-542

160 Possible Therapeutic Roles of Metallothionein-3 and Zinc in Endosome-Autophagosome-Lysosome Pathway (EALP) Dysfunction in Astrocytes. **2019**, 187-200

159 Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis.

158 Progranulin deficiency leads to reduced glucocerebrosidase activity.

157 Genetic contributions to sporadic frontotemporal dementia. **2020**, 71-88

156	Genetic Disruption of WASHC4 Drives Endo-lysosomal Dysfunction and Cognitive-Movement Impairments in Mice and Humans.	
155	Clinical and pathological phenotypes in dementia. **2020**, 147-164	
154	Early-onset phenotype of bi-allelic GRN mutations. **2021**, 144, e22	2
153	TDP-43 and neurodegenerative diseases. **2022**, 1-26	
152	Posttranslational modifications of TDP-43. **2022**, 45-79	
151	Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.. **2022**,	0
150	A Consensus Proteomic Analysis of Alzheimer's Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation.	1
149	Parkinson disease and related disorders. **2020**, 19-30	1
148	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. **2021**,	2
147	TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy. **2021**, 7, eabg3897	3
146	Neurodegenerative dementia and Parkinsonism.	
145	The clinical spectrum of frontotemporal dementia. **2018**, 69, 9-15	
144	Single-cell multimodal omics and directly reprogrammed neurons to probe reduced penetrance in Frontotemporal Dementia.	
143	TSC1 loss-of-function increases risk for tauopathy by inducing tau acetylation and preventing autophagy-mediated tau clearance.	1
142	The role of macrophage scavenger receptor 1 (Msr1) in prion pathogenesis.	
141	Neuropathology of non-Alzheimer degenerative disorders. **2009**, 3, 1-23	63
140	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. **2010**, 3, 129-43	16
139	A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation. **2011**, 26, 185-90	5

138	TDP-43 in aging and Alzheimer's disease - a review. **2011**, 4, 147-55	112
137	C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. **2012**, 1, 107-18	31
136	Circulating progranulin as a biomarker for neurodegenerative diseases. **2012**, 1, 180-90	19
135	Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers. **2014**, 3, 103-14	12
134	Potential effects of progranulin and granulins against retinal photoreceptor cell degeneration. **2019**, 25, 902-911	2
133	New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. **2021**, 72, 131-139	1
132	Glycosphingolipid metabolism and its role in ageing and Parkinson's disease. **2021**, 1	2
131	Diverse human astrocyte and microglial transcriptional responses to Alzheimer's pathology. **2021**, 143, 75	5
130	Mitochondria Dysfunction in Frontotemporal Dementia/Amyotrophic Lateral Sclerosis: Lessons From Models.. **2021**, 15, 786076	0
129	Concurrent tau pathologies in frontotemporal lobar degeneration with TDP-43 pathology. **2021**,	0
128	Two Rare Variants in and Genes-Do They Contribute to Semantic Dementia Clinical Phenotype?. **2021**, 12,	0
127	Increased Fat Taste Preference in Progranulin-Deficient Mice. **2021**, 13,	0
126	Parkin beyond Parkinson's Disease-A Functional Meaning of Parkin Downregulation in TDP-43 Proteinopathies.. **2021**, 10,	1
125	Aberrant TDP-43 phosphorylation: a key wind gap from TDP-43 to TDP-43 proteinopathy. **2021**, 7, 119-131	
124	Pathological phase transitions in ALS-FTD impair dynamic RNA-protein granules. **2021**,	1
123	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia.. **2022**, 16, 758182	0
122	Serum progranulin is not associated with rs5848 polymorphism in Korean patients with neurodegenerative diseases.. **2022**, 17, e0261007	
121	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers.. **2022**,	0

120	Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice.. **2022**, 23,	0
119	Interactions between weight loss and plasma neurodegenerative markers for determining cognitive decline among community-dwelling older adults.. **2022**,	2
118	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency.. **2022**, e109108	2
117	Protein synthesis modulation as a therapeutic approach for amyotrophic lateral sclerosis and frontotemporal dementia.. **2022**, 17, 1423-1430	0
116	Multiple Molecular Pathways Are Influenced by Progranulin in a Neuronal Cell Model-A Parallel Omics Approach.. **2021**, 15, 775391	1
115	Progranulin as a therapeutic target in neurodegenerative diseases.. **2022**,	5
114	Antisense oligonucleotide-based therapeutic strategy for progranulin-deficient frontotemporal dementia.	0
113	Regulation of lysosomal trafficking of progranulin by sortilin and prosaposin.. **2022**, 4, fcab310	0
112	Plasma Small Extracellular Vesicles with Complement Alterations in / and Sporadic Frontotemporal Lobar Degeneration.. **2022**, 11,	1
111	Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.. **2022**,	2
110	Differential regulation of progranulin derived granulin peptides.. **2022**, 17, 15	1
109	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration.. **2022**, 34, 102954	0
108	The severity of behavioural symptoms in FTD is linked to the loss of GABRQ-expressing VENs and pyramidal neurons.. **2022**,	0
107	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia.. **2022**, 23, 99	0
106	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. **2021**,	2
105	Clinical Trial Development in Frontotemporal Lobar Degeneration. **2022**, 216-231	
104	Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases.. **2022**,	5
103	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.. **2022**,	2

102	Inflammation and immune dysfunction in Parkinson disease.. **2022**,	23
101	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments.. **2022**, 12,	0
100	Progranulin deficiency promotes persistent neuroinflammation and causes regional pathology in the hippocampus following traumatic brain injury.. **2022**,	0
99	Protein interaction network analysis reveals genetic enrichment of immune system genes in frontotemporal dementia.. **2022**, 116, 67-79	0
98	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations.. **2021**,	0
97	Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.. **2021**, 14, 767041	3
96	Microglia and astrocyte involvement in neurodegeneration and brain cancer.. **2021**, 18, 298	2
95	Efficient progranulin exit from the ER requires its interaction with prosaposin, a Surf4 cargo.. **2022**, 221,	1
94	Transcriptomic analysis of frontotemporal lobar degeneration with TDP-43 pathology reveals cellular alterations across multiple brain regions.. **2021**, 143, 383	0
93	Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100´years.. **2022**, 1	0
92	Overexpression of progranulin increases pathological protein accumulation by suppressing autophagic flux.. **2022**, 611, 78-84	0
91	Table_1.DOCX. **2020**,	
90	Defects of Nutrient Signaling and Autophagy in Neurodegeneration.. **2022**, 10, 836196	1
89	Nuclear pore complexes - a doorway to neural injury in neurodegeneration.. **2022**,	0
88	The Interplay Between Autophagy and RNA Homeostasis: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.. **2022**, 10, 838402	
87	Progranulin Promotes Functional Recovery in Rats with Acute Spinal Cord Injury via Autophagy-Induced Anti-inflammatory Microglial Polarization.. **2022**, 1	0
86	Cell death in development, maintenance, and diseases of the nervous system.. **2022**,	0
85	Biological basis and psychiatric symptoms in frontotemporal dementia.. **2022**,	0

84	Abemaciclib and Vacuolin-1 induce vacuole-like autolysosome formation □A new tool to study autophagosome-lysosome fusion. **2022**,	
83	Advances in Treatment of Frontotemporal Dementia.. **2022**, appineuropsych21060166	1
82	The role of progranulin in ischemic heart disease and its related risk factors. **2022**, 106215	
81	Recent Advances in Frontotemporal Dementia. 1-34	
80	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. **2022**, 81, 387-413	0
79	How network-based approaches can complement gene identification studies in frontotemporal dementia. **2022**,	
78	Mapping the genetic landscape of early-onset Alzheimer□ disease in a cohort of 36 families. **2022**, 14,	0
77	Behavioral Variant Frontotemporal Dementia. **2022**, 28, 702-725	
76	Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.	0
75	GRN Mutations Are Associated with Lewy Body Dementia.	0
74	Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration. 10.1212/WNL.0000000000200860	0
73	Exome Sequencing of a Portuguese Cohort of Frontotemporal Dementia Patients: Looking Into the ALS-FTD Continuum. 13,	
72	Progranulin Preserves Autophagy Flux and Mitochondrial Function in Rat Cortical Neurons Under High Glucose Stress. 16,	1
71	Study of Alzheimer's disease- and Frontotemporal dementia- associated genes in the Cretan Aging Cohort. **2022**,	
70	Apolipoprotein L1 is increased in frontotemporal lobar degeneration post-mortem brain but not in ante-mortem cerebrospinal fluid. **2022**, 172, 105813	
69	Neuroimmune dysfunction in frontotemporal dementia: Insights from progranulin and C9orf72 deficiency. **2022**, 76, 102599	
68	Frontotemporal lobar degeneration. **2023**, 337-360	
67	Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex.	2

66	YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration. **2022**, 14,	0
65	A novel phenotype in an Italian family with a rare progranulin mutation.	
64	The New Zealand Genetic Frontotemporal Dementia Study (FTDGeNZ): a longitudinal study of pre-symptomatic biomarkers. 1-21	
63	Rare GRN mutation in a patient diagnosed´with primary progressive aphasia and´parkinsonism.	
62	Progranulin-derived granulin E and lysosome membrane protein CD68 interact to reciprocally regulate their protein homeostasis. **2022**, 102348	0
61	Differential Gene Expression in Sporadic and Genetic Forms of Alzheimer's Disease and Frontotemporal Dementia in Brain Tissue and Lymphoblastoid Cell Lines.	0
60	Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects. 13,	1
59	TMEM106B Acts as a Modifier of Cognitive and Motor Functions in Amyotrophic Lateral Sclerosis. **2022**, 23, 9276	1
58	Frequency and Longitudinal Course of Motor Signs In Genetic Frontotemporal Dementia. 10.1212/WNL.0000000000002008	0
57	Generation and Characterization of Novel iPSC Lines from a Portuguese Family Bearing Heterozygous and Homozygous GRN Mutations. **2022**, 10, 1905	0
56	How the immune system shapes neurodegenerative diseases. **2022**, 45, 733-748	0
55	Biomarkers for dementia in Latin American countries: Gaps and opportunities.	2
54	Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases. **2022**, 10, 2288	0
53	Familial Cerebellar Ataxia and Amyotrophic Lateral Sclerosis/Frontotemporal Dementia with DAB1 and C9ORF72 Repeat Expansions: An 18-Year Study.	0
52	Plasma Small Extracellular Vesicle Cathepsin D Dysregulation in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. **2022**, 23, 10693	1
51	The role of upstream lipid and metabolic systems in Alzheimer's disease, Parkinson's disease and dementias.	1
50	Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis. **2022**, 13,	1
49	The PINK1 p.Asn521Thr Variant Is Associated with Earlier Disease Onset in GRN/C9orf72 Frontotemporal Lobar Degeneration. **2022**, 23, 12847	0

48	Decreased Prosaposin and Progranulin in the Cingulate Cortex Are Associated with Schizophrenia Pathophysiology. **2022**, 23, 12056	0
47	Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia. **2022**,	0
46	Influences of rare protein-coding genetic variants on the human plasma proteome in 50,829 UK Biobank participants.	0
45	Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-up. 10.1212/WNL.0000000000201	0
44	Granulin Loss of Function in Human Mature Brain Organoids Implicates Astrocytes in TDP-43 Pathology.	0
43	Changing perspectives on frontotemporal dementia: A review.	1
42	A TDP-43 acetylation-mimic mutation that disrupts RNA-binding drives FTLD-like neurodegeneration in a mouse model of sporadic TDP-43 proteinopathy.	0
41	Microglial efferocytosis: Diving into the Alzheimer's disease gene pool. **2022**, 110, 3513-3533	1
40	GRN/C1 iPSC-derived cortical neurons recapitulate the pathological findings of both frontotemporal lobar degeneration and neuronal ceroidolipofuscinosis. **2022**, 175, 105891	0
39	Pathological 25 kDa C-Terminal Fragments of TDP-43 Are Present in Lymphoblastoid Cell Lines and Extracellular Vesicles from Patients Affected by Frontotemporal Lobar Degeneration and Neuronal Ceroidolipofuscinosis Carrying a GRN Mutation. **2022**, 23, 13753	0
38	Converging links between adult-onset neurodegenerative Alzheimer's disease and early life neurodegenerative neuronal ceroid lipofuscinosis?. **2023**, 18, 1463	0
37	TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?. **2022**, 23, 15755	0
36	Accumulation of TMEM106B C-terminal fragments in neurodegenerative disease and aging.	0
35	TNFR-1 and GDF-15 are associated with plasma neurofilament light chain and progranulin among community-dwelling older adults: a secondary analysis of the MAPT Study.	0
34	White matter abnormalities in presymptomatic GRN and C9orf72 mutation carriers.	0
33	Altered Blood–Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis. **2022**, 14, 2803	0
32	Reduced progranulin increases tau and alpha-synuclein inclusions and alters phenotypes of tauopathy mice via glucocerebrosidase.	0
31	Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches. 1-18	0

30	Extracellular Chaperone Networks and the Export of J-Domain Proteins. **2022**, 102840	0
29	RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy.	0
28	Tandem mass tag-based quantitative proteomics analysis reveals the new regulatory mechanism of progranulin in influenza virus infection. 13,	0
27	RNA-binding deficient TDP-43 drives cognitive decline in a mouse model of TDP-43 proteinopathy.	0
26	Astroglial toxicity promotes synaptic degeneration in the thalamocortical circuit in frontotemporal dementia with GRN mutations.	0
25	Progranulin from different gliocytes in the nucleus accumbens exerts distinct roles in FTD- and neuroinflammation-induced depression-like behaviors. **2022**, 19,	0
24	Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. **2023**, 13, 73	0
23	Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19. **2023**, 351-368	0
22	Progranulin (PGRN) as a regulator of inflammation and a critical factor in the immunopathogenesis of cardiovascular diseases. **2023**, 20,	0
21	Plasma lysosphingolipids in GRN-related diseases: Monitoring lysosomal dysfunction to track disease progression. **2023**, 181, 106108	0
20	The unique neuropathological vulnerability of the human brain to aging. **2023**, 87, 101916	0
19	hiPSC-derived GRN-deficient astrocytes delay spiking activity of developing neurons. **2023**, 181, 106124	0
18	Lack of a protective effect of the Tmem106b protective SNP in the Grn knockout mouse model for frontotemporal lobar degeneration. **2023**, 11,	0
17	Insights into the promising prospect of medicinal chemistry studies against neurodegenerative disorders. **2023**, 373, 110375	0
16	Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases. **2023**, 12,	0
15	SorCS2 binds progranulin and regulates motor axon outgrowth.	0
14	Preclinical Interventions in Mouse Models of Frontotemporal Dementia Due to Progranulin Mutations. **2023**, 20, 140-153	0
13	The Benson Complex Figure Test detects deficits in visuoconstruction and visual memory in symptomatic familial frontotemporal dementia: A GENFI study. **2023**, 446, 120590	0

12	Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology. **2023**, 18, 706-719	0
11	Depletion and activation of microglia impact metabolic connectivity of the mouse brain. **2023**, 20,	0
10	Multi-modal Proteomic Characterization of Lysosomal Function and Proteostasis in Progranulin-Deficient Neurons.	0
9	Progranulin Deficiency Induces Mitochondrial Dysfunction in Frontotemporal Lobar Degeneration with TDP-43 Inclusions. **2023**, 12, 581	0
8	Targeting nonsense-mediated RNA decay does not increase progranulin levels in the Grn R493X mouse model of frontotemporal dementia. **2023**, 18, e0282822	0
7	Progranulin Oncogenic Network in Solid Tumors. **2023**, 15, 1706	0
6	Progranulin Gene Mutation in Chinese Patients with Frontotemporal Dementia: A Case Report and Literature Review. **2023**, 1-10	0
5	Disrupted myelin lipid metabolism differentiates frontotemporal dementia caused by GRN and C9orf72 gene mutations. **2023**, 11,	0
4	Genetic variation associated with human longevity and Alzheimer's disease risk act through microglia and oligodendrocyte cross-talk.	0
3	Progranulin inhibits phospholipase sPLA2-IIA to control neuroinflammation.	0
2	FTD-associated behavioural and transcriptomic abnormalities in 'humanized' progranulin-deficient mice: A novel model for progranulin-associated FTD. **2023**, 182, 106138	0
1	Progranulin deficiency results in sex-dependent alterations in microglia in response to demyelination.	0